Original Article

Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients

The Heart Outcomes Prevention Evaluation Study Investigators

N Engl J Med 2000; 342:154-160January 20, 2000

Abstract

Background

Observational and experimental studies suggest that the amount of vitamin E ingested in food and in supplements is associated with a lower risk of coronary heart disease and atherosclerosis.

Full Text of Background...

Methods

We enrolled a total of 2545 women and 6996 men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. These patients were randomly assigned according to a two-by-two factorial design to receive either 400 IU of vitamin E daily from natural sources or matching placebo and either an angiotensin-converting–enzyme inhibitor (ramipril) or matching placebo for a mean of 4.5 years (the results of the comparison of ramipril and placebo are reported in a companion article). The primary outcome was a composite of myocardial infarction, stroke, and death from cardiovascular causes. The secondary outcomes included unstable angina, congestive heart failure, revascularization or amputation, death from any cause, complications of diabetes, and cancer.

Full Text of Methods...

Results

A total of 772 of the 4761 patients assigned to vitamin E (16.2 percent) and 739 of the 4780 assigned to placebo (15.5 percent) had a primary outcome event (relative risk, 1.05; 95 percent confidence interval, 0.95 to 1.16; P=0.33). There were no significant differences in the numbers of deaths from cardiovascular causes (342 of those assigned to vitamin E vs. 328 of those assigned to placebo; relative risk, 1.05; 95 percent confidence interval, 0.90 to 1.22), myocardial infarction (532 vs. 524; relative risk, 1.02; 95 percent confidence interval, 0.90 to 1.15), or stroke (209 vs. 180; relative risk, 1.17; 95 percent confidence interval, 0.95 to 1.42). There were also no significant differences in the incidence of secondary cardiovascular outcomes or in death from any cause. There were no significant adverse effects of vitamin E.

Full Text of Results...

Conclusions

In patients at high risk for cardiovascular events, treatment with vitamin E for a mean of 4.5 years has no apparent effect on cardiovascular outcomes.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 1Kaplan–Meier Estimates of the Effect of Vitamin E on the Composite Outcome of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Causes.

Figure 3Kaplan–Meier Estimates of the Effect of Vitamin E on the Incidence of Death from Any Cause.

Article Activity

406 articles have cited this article

Article

Oxidative modification of low-density lipoprotein is an important step in the development and progression of atherosclerosis in experimental studies,1,2 and antioxidants such as vitamin E have been shown to slow atherosclerosis.3-5 An inverse relation has been observed between coronary heart disease and the consumption of fruits, vegetables, and other foods containing vitamins, particularly vitamin E.6-9 Observational studies have indicated that persons who consume more than 100 IU of vitamin E a day for more than two years have lower rates of coronary events10,11 and lower rates of progression of coronary artery lesions.12 However, observational studies cannot distinguish whether the lower risk of coronary heart disease associated with higher levels of vitamin E consumption is due to the vitamin or to other associated lifestyle factors such as increased exercise and other aspects of diet. There have been four randomized, controlled trials of the relation between vitamin E and coronary heart disease,13-16 but their results are conflicting, perhaps because of the low doses of vita-min E used in some studies,13,14 the small numbers of events,15 or the limited duration of treatment.15,16

We evaluated a high dose (400 IU per day) of vitamin E from natural sources, which has high bioavailability, in a large, five-year, prospective study of patients at high risk for cardiovascular events. The primary outcome was a composite of myocardial infarction, stroke, and death from cardiovascular causes. The secondary outcomes included death from any cause, hospitalization for unstable angina or congestive heart failure, revascularization or limb amputation, complications of diabetes, and cancer. The trial was also designed to evaluate the effects of an angiotensin-converting–enzyme inhibitor, ramipril, on the incidence of cardiovascular events. After nearly 4.5 years of follow-up, the collection of data on cardiovascular disease was stopped in April 1999 on the basis of a finding by the independent data and safety monitoring board that the trial had conclusively demonstrated the benefits of ramipril and a lack of effect of vitamin E on cardiovascular events. This report presents our findings relating to the effects of vitamin E on the primary and secondary cardiovascular outcomes. The study has been continued in the majority of centers to evaluate the effects of vitamin E on the incidence of cancer.

Methods

Study Design

The Heart Outcomes Prevention Evaluation (HOPE) Study is a double-blind, randomized trial with a two-by-two factorial design, conducted to evaluate the effects of ramipril and vitamin E in 9541 patients at high risk for cardiovascular events. The results of the comparison of ramipril with placebo are reported in a companion article.17 Details of the methods are given in that article17 and in a previously published article.18 Briefly, eligible patients at high risk were randomly assigned to receive either 400 IU of vitamin E from natural sources or an equivalent placebo daily for 4 to 6 years (mean, 4.5) and in addition to receive either 10 mg of ramipril or an equivalent placebo daily. Patients were evaluated every six months for a variety of outcomes.

Outcomes

The primary outcome was a composite of myocardial infarction, stroke, and death from cardiovascular causes. Deaths classified as due to cardiovascular causes were unexpected deaths presumed to be due to ischemic cardiovascular disease and occurring within 24 hours after the onset of symptoms without clinical or postmortem evidence of another cause; deaths from myocardial infarction or stroke that occurred within seven days after the myocardial infarction or stroke; and deaths from congestive heart failure, dysrhythmia, pulmonary embolism, or ruptured abdominal aortic aneurysm. Deaths for which the cause was uncertain were presumed to be due to cardiovascular disease. Myocardial infarction was diagnosed when two of the following three criteria were met: typical symptoms, increased cardiac enzyme levels (at least twice the upper limit of normal), and diagnostic electrocardiographic changes. Stroke was defined as a neurologic deficit lasting more than 24 hours. A computed tomographic or magnetic resonance imaging examination was recommended to define the type of stroke.

Secondary and other outcomes were death from any cause; unstable angina, defined as worsening angina or angina at rest requiring hospitalization; hospitalization for heart failure with clinical and radiologic signs of congestion; revascularization or limb amputation; the development of overt nephropathy or the need for dialysis or laser therapy among patients with diabetes; and the development of heart failure or new or worsening angina regardless of the need for hospitalization.

Results

Characteristics of the Patients

The characteristics of the 9541 patients are shown in Table 1Table 1Base-Line Characteristics of the Patients.. The rate of compliance with the assigned regimen was high throughout the study. The percentages of patients who were taking vitamin E in the vitamin E and placebo groups, respectively, were 94.2 percent and 1.0 percent at one year, 93.3 percent and 1.7 percent at two years, 91.3 percent and 2.0 percent at three years, 90.2 percent and 2.7 percent at four years, and 89.2 percent and 3.4 percent at the final visit.

Primary Cardiovascular Outcomes and Deaths from Any Cause

A total of 772 of the 4761 patients who were assigned to receive vitamin E (16.2 percent) and 739 of the 4780 who were assigned to placebo (15.5 percent) had a primary cardiovascular event (relative risk, 1.05; 95 percent confidence interval, 0.95 to 1.16; P=0.33) (Table 2Table 2Incidence of the Primary Outcome and of Deaths from Any Cause. and Figure 1Figure 1Kaplan–Meier Estimates of the Effect of Vitamin E on the Composite Outcome of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Causes.). There were no significant differences between the groups in the numbers of deaths from cardiovascular causes (342 in the vitamin E group vs. 328 in the placebo group; relative risk, 1.05), myocardial infarctions (532 vs. 524; relative risk, 1.02), deaths from coronary heart disease (287 vs. 277; relative risk, 1.06), or strokes (209 vs. 180; relative risk, 1.17) (Figure 2Figure 2Kaplan–Meier Estimates of the Effect of Vitamin E on the Incidence of Myocardial Infarction (Panel A) and Stroke (Panel B). and Figure 3Figure 3Kaplan–Meier Estimates of the Effect of Vitamin E on the Incidence of Death from Any Cause.). The total numbers of deaths were similar in the two groups (535 vs. 537; relative risk, 1.00). Vitamin E had no signifi-cant effect on the primary outcome either among patients who were receiving ramipril (338 events among those who were receiving vitamin E and 313 events among those who were receiving placebo; relative risk, 1.08) or among patients who were not receiving ramipril (421 and 405 events, respectively; relative risk, 1.05).

Secondary Cardiovascular and Combined Outcomes

There were no differences between patients assigned to vitamin E and those assigned to placebo in the number of hospitalizations for unstable angina (586 vs. 569; relative risk, 1.04), hospitalizations for heart failure (160 vs. 144; relative risk, 1.12), or revascularizations or limb amputations (848 vs. 787; relative risk, 1.09) (Table 3Table 3Incidence of Secondary and Other Outcomes.). There were no significant differences in the number of patients with angina of new onset (278 vs. 245; relative risk, 1.15) or microvascular complications of diabetes (340 vs. 325; relative risk, 1.06). A combined analysis of the proportion of patients who had any primary or secondary event found a nonsignificantly higher rate among those assigned to vitamin E (1630 vs. 1576; relative risk, 1.05; 95 percent confidence interval, 0.98 to 1.13; P=0.14).

Subgroup Analyses

There was no heterogeneity of results among subgroups defined according to sex, age, previous cardiovascular disease, or use of other drugs with respect to the primary or secondary outcomes (data not shown). Specifically, there was no significant difference in the incidence of the primary outcome among patients with diabetes (325 of those assigned to vitamin E vs. 313 of those assigned to placebo; relative risk, 1.04) or among smokers (135 vs. 139; relative risk, 1.02).

Adverse Effects

There was no significant difference between groups in the incidence of adverse effects or in the number of patients who stopped taking the study medication. There was no increase in hemorrhagic stroke associated with vitamin E use (17 of those assigned to vitamin E had hemorrhagic stroke, as compared with 13 of those assigned to placebo) or among those who were also taking an antiplatelet agent (11 vs. 8).

Discussion

In our study, vitamin E did not reduce the incidence of cardiovascular events, as compared with the incidence among patients assigned to placebo, during a follow-up period of four to six years. Given the large number of events and the consistent lack of difference in all secondary cardiovascular outcomes, it is very unlikely that vitamin E had any clinically worthwhile beneficial effect on cardiovascular disease during four or five years of treatment.

Results have been reported from four randomized trials of the effects of vitamin E on cardiovascular events. In a Chinese study, 29,584 adults from Linxian Province, who did not have cardiovascular disease at entry, were randomly assigned to receive daily vitamin E (30 mg), beta carotene, and selenium supplements or to receive placebo.13 During the 5.2 years of follow-up, there was a 9 percent decrease in deaths from any cause without any significant reduction in cardiovascular events. The dose of vitamin E in this study was small, the nutritional status and cardiovascular risk of this population were very different from those of Western populations, and the beneficial effects on overall mortality cannot be attributed only to vitamin E.

The second trial was the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study, involving 29,133 male smokers who were 50 to 69 years of age.14 Daily treatment with 50 mg of vitamin E for five to eight years had no effect on the risk of death from coronary heart disease. In a subgroup of 1862 men with a previous myocardial infarction at entry, there was a nonsignificant increase in the risk of death from coronary heart disease (relative risk, 1.33; 95 percent confidence interval, 0.86 to 2.05; P=0.20). However, a reduction in the risk of nonfatal myocardial infarction was documented among men assigned to vitamin E only (40 vs. 55; relative risk, 0.62; 95 percent confidence interval, 0.41 to 0.96), but not among those receiving the combination of vitamin E and beta carotene, in comparison with those receiving placebo only.19 In this subgroup, the number of events was small. In the remaining patients in this study, there was no significant effect of vitamin E on nonfatal or fatal myocardial infarction, despite large numbers of events (1204 and 907, respectively).20 Thus, in this well-conducted trial, vitamin E had no effect on coronary heart disease. Although the trial used a low dose of synthetic vitamin E (50 mg per day), the median level of alpha-tocopherol increased significantly, from 28.5 μmol per liter at base line to 42.5 μmol per liter at three months.

The third trial was the Cambridge Heart Antioxidant Study, which randomly assigned 2002 patients with coronary atherosclerosis to receive either vitamin E or placebo.15 The mean alpha-tocopherol levels increased from 34.2 to 51.1 μmol per liter in patients receiving 400 IU of vitamin E per day and to 64.5 μmol per liter in patients receiving 800 IU per day. The majority of the patients received 400 IU per day. After a median follow-up of 1.4 years, a large reduction in the number of patients with nonfatal myocardial infarction was observed (14 in the vitamin E group vs. 41 in the placebo group; relative risk, 0.53; 95 percent confidence interval, 0.11 to 0.47; P= 0.005), but there was no difference in deaths due to cardiovascular causes (27 vs. 23; relative risk, 1.18; 95 percent confidence interval, 0.62 to 2.27; P=0.61). In this trial, the number of events was small and there were imbalances in several base-line characteristics that call into question whether randomization resulted in truly comparable groups.

Furthermore, the very large reduction in nonfatal myocardial infarction within a relatively short time (median, 1.4 years) is inconsistent with the results of other interventions, such as lipid-lowering agents or antihypertensive medications, that reduce cardiovascular events. It is therefore likely that the results of the Cambridge Heart Antioxidant Study may have been due to chance. This possibility is supported by the results of a recent Italian trial,16 in which 11,000 patients who had had myocardial infarctions were randomly assigned to receive 300 IU of vitamin E per day or placebo for a median of 3.5 years. The number of patients with nonfatal myocardial infarction was slightly higher in the vitamin E group than the placebo group (295 vs. 284; relative risk, 1.02; 95 percent confidence interval, 0.87 to 1.21), and the number of deaths from coronary heart disease was slightly smaller (227 vs. 249; relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.11). Neither difference was statistically significant.16

Our study used a high dose of vitamin E (400 IU per day), had high rates of compliance, and involved high-risk patients. The study had a large number of primary outcomes and therefore had high statistical power (more than 90 percent power to detect a 13 percent relative reduction in the risk of the primary outcome). Furthermore, a large number of secondary outcomes (e.g., revascularization or limb amputation, unstable angina, worsening angina, and heart failure) were examined. Such data are not available from most trials. Combining the data from all trials of vitamin E indicates that such treatment has little effect on the risk of death or cardiovascular events (Table 4Table 4Meta-Analysis of the Effects of Vitamin E on Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in Large Trials.), at least over a four-to-six-year period.

Steinberg has hypothesized that unlike agents that lower cholesterol or blood pressure, antioxidants may have to be used for more than five years to have a demonstrable benefit, since the primary mechanism of these agents may be the prevention of new lesions.22 Therefore, in a population like the one we studied, it may take longer than five years to detect an effect on clinical outcomes. However, the Physicians' Health Study did not find a benefit of beta carotene (another antioxidant with a different action) after 12 years.23 Similar data are not available for vitamin E, but observational studies that demonstrated a lower rate of coronary heart disease with vitamin E supplementation suggested that a lower risk should be evident after two years.10,11 In a nested substudy, we are examining whether the thickness of the carotid intima and media (an indication of the risk of early atherosclerosis) can be favorably altered by vitamin E.24 If so, Steinberg's hypothesis may be worth exploring with more prolonged follow-up or treatment to assess whether such changes in the development of atherosclerosis would translate into a benefit in terms of clinical outcomes.

Although the moderate duration of vitamin E supplementation (four to six years) and the characteristics of the population may explain our finding of a lack of benefit of vitamin E, another reason may be our use of vitamin E alone, without other antioxidants. In the epidemiologic studies that found an association between higher dietary intake of vitamin E and lower rates of coronary heart disease, higher vitamin E consumption was also associated with higher intake of a number of other antioxidants and micronutrients.6-9 It is possible that vitamin E supplementation requires these cofactors to have a beneficial effect.25 Although the existence of interactions between vitamin E and other vitamins,10 beta carotene,6,14 or selenium13 is not supported by the findings of prospective observational studies or randomized trials, this hypothesis can be tested only in trials in which combinations of vitamins are given; some such trials are now in progress.26-28

In conclusion, 400 IU of vitamin E administered daily for four to six years had no beneficial effects on cardiovascular outcomes in a high-risk population of patients who were 55 years of age or older. Vita-min E was well tolerated, with no significant adverse events as compared with placebo. This finding provides some reassurance for the conduct of large, longer-term trials to address unanswered questions regarding vitamin E, such as its possible effects in preventing cancer.

Funded by the Medical Research Council of Canada, Natural Source Vitamin E Association, Negma, Hoechst–Marion Roussel, AstraZeneca, King Pharmaceuticals, and the Heart and Stroke Foundation of Ontario. Dr. Yusuf was supported by a Senior Scientist Award of the Medical Research Council of Canada and a Heart and Stroke Foundation of Ontario Research Chair.

The writing group (Salim Yusuf, D.Phil., Gilles Dagenais, M.D., Janice Pogue, M.Sc., Jackie Bosch, M.Sc., and Peter Sleight, D.M.) assumes responsibility for the overall content and integrity of the manuscript.

We are indebted to W. Whitehill, F. Schutze, N. Bender, B. Rangoonwala, A. Ljunggren, G. Olsson, J.C. Dairon, J. Ghadiali, B. Carter, J.P. St. Pierre, W. Schulz, M. Jensen, L. Rios-Nogales, M. Bravo, J. Bourgouin, and C. Vint-Reed for support and to Karin Dearness for secretarial help.

Source Information

Address reprint requests to Dr. Salim Yusuf at the Canadian Cardiovascular Collaboration Project Office, Hamilton General Hospital, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada, or at yusufs@fhs.mcmaster.ca.

The investigators are listed in the Appendix of the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000;342:145-53.

References

References

1. 1

   Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924
   Full Text | Web of Science | Medline

2. 2

   Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-795
   CrossRef | Web of Science | Medline

3. 3

   Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987;84:7725-7729
   CrossRef | Web of Science | Medline

4. 4

   Verlangieri AJ, Bush MJ. Effects of δ-α-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 1992;11:131-138
   Web of Science | Medline

5. 5

   Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992;94:153-159
   CrossRef | Web of Science | Medline

6. 6

   Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994;139:1180-1189
   Web of Science | Medline

7. 7

   Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 1995;5:255-260
   CrossRef | Medline

8. 8

   Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156-1162
   Full Text | Web of Science | Medline

9. 9

   Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999;69:261-266
   Web of Science | Medline

10. 10

    Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-1449
    Full Text | Web of Science | Medline

11. 11

    Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-1456
    Full Text | Web of Science | Medline

12. 12

    Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995;273:1849-1854
    CrossRef | Web of Science | Medline

13. 13

    Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492
    CrossRef | Web of Science | Medline

14. 14

    The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035
    Full Text | Web of Science | Medline

15. 15

    Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996;347:781-786
    CrossRef | Web of Science | Medline

16. 16

    GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-455
    CrossRef | Web of Science | Medline

17. 17

    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
    Full Text | Web of Science | Medline

18. 18

    The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-137
    Web of Science | Medline

19. 19

    Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:1715-1720
    CrossRef | Web of Science | Medline

20. 20

    Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998;158:668-675
    CrossRef | Web of Science | Medline

21. 21

    Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371
    CrossRef | Web of Science | Medline

22. 22

    Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995;346:36-38
    CrossRef | Web of Science | Medline

23. 23

    Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-1149
    Full Text | Web of Science | Medline

24. 24

    Lonn EM, Yusuf S, Doris CI, et al. Study design and baseline characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE. Am J Cardiol 1996;78:914-919
    CrossRef | Web of Science | Medline

25. 25

    Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 1999;13:977-994
    Web of Science | Medline

26. 26

    Hercberg S, Galan P, Preziosi P, et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant and minerals to reduce cardiovascular diseases and cancers: SUpplementation en VItamines et Mineraux AntioXydants Study. Int J Vitam Nutr Res 1998;68:3-20
    Web of Science | Medline

27. 27

    MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-741
    CrossRef | Web of Science | Medline

28. 28

    Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995;123:860-872
    Web of Science | Medline

Citing Articles (406)

Citing Articles

1. 1

   Eric A. Klein, Ian M. Thompson. (2012) Chemoprevention of prostate cancer: an updated view. World Journal of Urology
   CrossRef

2. 2

   Zain Ahmed, W. H. Wilson Tang. (2012) Pharmacologic Strategies to Target Oxidative Stress in Heart Failure. Current Heart Failure Reports
   CrossRef

3. 3

   Jodi Tinkel, Hamdy Hassanain, Samer J. Khouri. (2012) Cardiovascular Antioxidant Therapy. Cardiology in Review1
   CrossRef

4. 4

   Anita P. Mayer, Julia A. Files, Sharonne N. Hayes. (2011) Let's (Not) Do It Again: Secondary Prevention of Cardiovascular Disease in Women. Journal of Women's Health111213072049009
   CrossRef

5. 5

   B Julie He, Mei-ling A Joiner, Madhu V Singh, Elizabeth D Luczak, Paari Dominic Swaminathan, Olha M Koval, William Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan, Kathy Zimmerman, Isabella M Grumbach, Robert M Weiss, Douglas R Spitz, Curt D Sigmund, W Matthijs Blankesteijn, Stephane Heymans, Peter J Mohler, Mark E Anderson. (2011) Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Medicine
   CrossRef

6. 6

   Robert Skully, Aroob Shanaah Saleh. (2011) Aging and the Effects of Vitamins and Supplements. Clinics in Geriatric Medicine 27:4, 591-607
   CrossRef

7. 7

   Jeff S Coombes, Robert G Fassett. (2011) Antioxidant therapy in hemodialysis patients: a systematic review. Kidney International
   CrossRef

8. 8

   Amaar Ujeyl, James C. Fang, Akshay S. Desai, Gilbert H. Mudge, Michael M. Givertz. (2011) Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-Year follow-up from a randomized, controlled study. The Journal of Heart and Lung Transplantation 30:10, 1200-1201
   CrossRef

9. 9

   Elisabeth Fabian, M. Bogner, A. Kickinger, K. -H. Wagner, I. Elmadfa. (2011) Vitamin status in elderly people in relation to the use of nutritional supplements. The journal of nutrition, health & aging
   CrossRef

10. 10

    Sona Mitra, Abhishek Deshmukh, Rajesh Sachdeva, Jingjun Lu, Jawahar L. Mehta. (2011) Oxidized Low-Density Lipoprotein and Atherosclerosis Implications in Antioxidant Therapy. The American Journal of the Medical Sciences 342:2, 135-142
    CrossRef

11. 11

    Vinay Prasad. (2011) Perspective: Why There Must Be a Meditative Medicine. Alternative and Complementary Therapies 17:5, 274-278
    CrossRef

12. 12

    Garth J.S. Cooper. (2011) Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs Disease. Drugs 71:10, 1281-1320
    CrossRef

13. 13

    Sagit Zolotov, Dafna Ben Yosef, Naphtali D Rishe, Yelena Yesha, Eddy Karnieli. (2011) Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. Personalized Medicine 8:4, 445-456
    CrossRef

14. 14

    Hong Wang, Yue-Jin Yang, Hai-Yan Qian, Qian Zhang, Hui Xu, Jian-Jun Li. (2011) Resveratrol in cardiovascular disease: what is known from current research?. Heart Failure Reviews
    CrossRef

15. 15

    Tommaso Gori, Thomas Münzel. (2011) Oxidative stress and endothelial dysfunction: Therapeutic implications. Annals of Medicine 43:4, 259-272
    CrossRef

16. 16

    Christoph Maack, Michael Böhm. (2011) Targeting Mitochondrial Oxidative Stress in Heart Failure. Journal of the American College of Cardiology 58:1, 83-86
    CrossRef

17. 17

    William D. Shrader, Akiko Amagata, Adam Barnes, Gregory M. Enns, Andrew Hinman, Orion Jankowski, Viktoria Kheifets, Ryo Komatsuzaki, Edgar Lee, Paul Mollard, Katsuyuki Murase, Alfredo A. Sadun, Martin Thoolen, Kieron Wesson, Guy Miller. (2011) α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. Bioorganic & Medicinal Chemistry Letters 21:12, 3693-3698
    CrossRef

18. 18

    B Freidlin, E L Korn. (2011) Assessing causal relationships between treatments and clinical outcomes: always read the fine print. Bone Marrow Transplantation
    CrossRef

19. 19

    Mae Sheikh-Ali, Joe M Chehade, Arshag D Mooradian. (2011) The Antioxidant Paradox in Diabetes Mellitus. American Journal of Therapeutics 18:3, 266-278
    CrossRef

20. 20

    Arianna Vignini, Alessandro Alidori, Luca Montesi, Francesca Raffaelli, Laura Nanetti, Enrico Bertoli, Laura Mazzanti. (2011) Vitamin E, diabetes and related diseases: an update. Mediterranean Journal of Nutrition and Metabolism 4:1, 3-9
    CrossRef

21. 21

    Rosalinda Madonna, Raffaele De Caterina. (2011) Cellular and molecular mechanisms of vascular injury in diabetes — Part II: Cellular mechanisms and therapeutic targets. Vascular Pharmacology 54:3-6, 75-79
    CrossRef

22. 22

    Rafael Monge-Rojas, Hannia Campos. (2011) Tocopherol and carotenoid content of foods commonly consumed in Costa Rica. Journal of Food Composition and Analysis 24:2, 202-216
    CrossRef

23. 23

    S. Bernardi, R. Candido, B. Toffoli, R. Carretta, B. Fabris. (2011) Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. Nephrology Dialysis Transplantation 26:3, 832-838
    CrossRef

24. 24

    Balazs Debreceni, Laszlo Debreceni. (2011) Why Do Homocysteine-Lowering B Vitamin and Antioxidant E Vitamin Supplementations Appear To Be Ineffective in the Prevention of Cardiovascular Diseases?. Cardiovascular Therapeuticsno-no
    CrossRef

25. 25

    T. Sekijima, A. Tanabe, R. Maruoka, N. Fujishiro, S. Yu, S. Fujiwara, H. Yuguchi, Y. Yamashita, Y. Terai, M. Ohmichi. (2011) Impact of platinum-based chemotherapy on the progression of atherosclerosis. Climacteric 14:1, 31-40
    CrossRef

26. 26

    Asaf A Qureshi, Charles W Karpen, Nilofer Qureshi, Christopher J Papasian, David C Morrison, John D Folts. (2011) Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Lipids in Health and Disease 10:1, 58
    CrossRef

27. 27

    D Mahalingam, A K Radhakrishnan, Z Amom, N Ibrahim, K Nesaretnam. (2011) Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. European Journal of Clinical Nutrition 65:1, 63-69
    CrossRef

28. 28

    William H. Shrank, Amanda R. Patrick, M. Alan Brookhart. (2011) Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians. Journal of General Internal Medicine
    CrossRef

29. 29

    A. Y. Estevez, J. S. Erlichman. 2011. Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. , 255-288.
    CrossRef

30. 30

    Gabriela M. Kuster, Stéphanie P. Häuselmann, Berit I. Rosc-Schlüter, Vera Lorenz, Otmar Pfister. (2010) Reactive Oxygen/Nitrogen Species and the Myocardial Cell Homeostasis: An Ambiguous Relationship. Antioxidants & Redox Signaling 13:12, 1899-1910
    CrossRef

31. 31

    2010. Scientific Rationale of Current Trends in Clinical Studies of Micronutrients for Prevention of Chronic Diseases. , 23-34.
    CrossRef

32. 32

    2010. Role of Micronutrients in the Prevention of Coronary Artery Disease and Improvement of the Standard Therapy. , 55-76.
    CrossRef

33. 33

    Jim I. Mann. (2010) Evidence-based nutrition: Does it differ from evidence-based medicine?. Annals of Medicine 42:7, 475-486
    CrossRef

34. 34

    Tomoaki Mikami, Toru Ichiseki, Ayumi Kaneuji, Yoshimichi Ueda, Tanzo Sugimori, Kiyokazu Fukui, Tadami Matsumoto. (2010) Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. Journal of Orthopaedic Science 15:5, 674-677
    CrossRef

35. 35

    Cathi Dennehy, Candy Tsourounis. (2010) A review of select vitamins and minerals used by postmenopausal women. Maturitas 66:4, 370-380
    CrossRef

36. 36

    T. Byers. (2010) Anticancer Vitamins du Jour--The ABCED's So Far. American Journal of Epidemiology 172:1, 1-3
    CrossRef

37. 37

    P. P. Singh, Anu Chandra, Farzana Mahdi, Ajanta Roy, Praveen Sharma. (2010) Reconvene and Reconnect the Antioxidant Hypothesis in Human Health and Disease. Indian Journal of Clinical Biochemistry 25:3, 225-243
    CrossRef

38. 38

    Shany Blum, Moshe Vardi, Nina S. Levy, Rachel Miller-Lotan, Andrew P. Levy. (2010) The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 211:1, 25-27
    CrossRef

39. 39

    Ulrich Förstermann. (2010) Nitric oxide and oxidative stress in vascular disease. Pflügers Archiv - European Journal of Physiology 459:6, 923-939
    CrossRef

40. 40

    Adonis Saremi, Rohit Arora. (2010) Vitamin E and Cardiovascular Disease. American Journal of Therapeutics 17:3, e56-e65
    CrossRef

41. 41

    Shany Blum, Moshe Vardi, Jonathan B Brown, Allen Russell, Uzi Milman, Chen Shapira, Nina S Levy, Rachel Miller-Lotan, Rabea Asleh, Andrew P Levy. (2010) Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11:5, 675-684
    CrossRef

42. 42

    Zorabel Cordero, Dagmar Drogan, Cornelia Weikert, Heiner Boeing. (2010) Vitamin E and Risk of Cardiovascular Diseases: A Review of Epidemiologic and Clinical Trial Studies. Critical Reviews in Food Science and Nutrition 50:5, 420-440
    CrossRef

43. 43

    B G Schwartz, C Economides, G S Mayeda, S Burstein, R A Kloner. (2010) The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. International Journal of Impotence Research 22:2, 77-90
    CrossRef

44. 44

    Corey E. Tabit, William B. Chung, Naomi M. Hamburg, Joseph A. Vita. (2010) Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders 11:1, 61-74
    CrossRef

45. 45

    William I. Sivitz, Mark A. Yorek. (2010) Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities. Antioxidants & Redox Signaling 12:4, 537-577
    CrossRef

46. 46

    Kailash Prasad. (2010) Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia. Molecular and Cellular Biochemistry 335:1-2, 67-74
    CrossRef

47. 47

    Daniel G. Federman, Sarah A. Stechschulte, Robert S. Kirsner. (2010) The Reply. The American Journal of Medicine 123:2, e19
    CrossRef

48. 48

    Andrew P. Levy, Rabea Asleh, Shany Blum, Nina S. Levy, Rachel Miller-Lotan, Shiri Kalet-Litman, Yefim Anbinder, Orit Lache, Farid M. Nakhoul, Roy Asaf, Dan Farbstein, Mordechai Pollak, Yitzhak Z. Soloveichik, Merav Strauss, Jonia Alshiek, Alina Livshits, Avery Schwartz, Hoda Awad, Kheir Jad, Hagit Goldenstein. (2010) Haptoglobin: Basic and Clinical Aspects. Antioxidants & Redox Signaling 12:2, 293-304
    CrossRef

49. 49

    Rabea Asleh, Andrew P. Levy. (2010) Divergent Effects of α -Tocopherol and Vitamin C on the Generation of Dysfunctional HDL Associated with Diabetes and the Hp 2-2 Genotype. Antioxidants & Redox Signaling 12:2, 209-217
    CrossRef

50. 50

    T.-M. Lee, P.-Y. Lai, N.-C. Chang. (2010) Effect of N-acetylcysteine on sympathetic hyperinnervation in post-infarcted rat hearts. Cardiovascular Research 85:1, 137-146
    CrossRef

51. 51

    M P C Kao, D S C Ang, A Pall, A D Struthers. (2010) Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. Journal of Human Hypertension 24:1, 1-8
    CrossRef

52. 52

    Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
    CrossRef

53. 53

    R. F. Mapanga, C. T. Musabayane. (2010) The Renal Effects of Blood Glucose-Lowering Plant-Derived Extracts in Diabetes Mellitus—an Overview. Renal Failure 32:1, 132-138
    CrossRef

54. 54

    D. A. Brown, W. E. Cascio. (2009) 'Leaky' ryanodine receptors and sudden cardiac death. Cardiovascular Research 84:3, 343-344
    CrossRef

55. 55

    Dimitrios Toumpanakis, Maria-Helena Karatza, Paraskevi Katsaounou, Charis Roussos, Spyros Zakynthinos, Andreas Papapetropoulos, Theodoros Vassilakopoulos. (2009) Antioxidant Supplementation Alters Cytokine Production From Monocytes. Journal of Interferon & Cytokine Research 29:11, 741-748
    CrossRef

56. 56

    P. P. Singh, Farzana Mahadi, Ajanta Roy, Praveen Sharma. (2009) Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. Indian Journal of Clinical Biochemistry 24:4, 324-342
    CrossRef

57. 57

    Alison M Hill, Jennifer A Fleming, Penny M Kris-Etherton. (2009) The role of diet and nutritional supplements in preventing and treating cardiovascular disease. Current Opinion in Cardiology 24:5, 433-441
    CrossRef

58. 58

    Jakub J. Regieli, J. Wouter Jukema, Pieter A. Doevendans, Aeilko H. Zwinderman, John J. Kastelein, Diederick E. Grobbee, Yolanda van der Graaf. (2009) Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease. Journal of the American College of Cardiology 54:14, 1238-1245
    CrossRef

59. 59

    Olga Pechanova, Fedor Simko. (2009) Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. Journal of Hypertension 27:Suppl 6, S32-S36
    CrossRef

60. 60

    Louai Razzouk, Michael E. Farkouh. (2009) Imaging outcomes in cardiovascular clinical trials. Nature Reviews Cardiology 6:8, 524-531
    CrossRef

61. 61

    Maurice W. Dysken, Laura Nelson Kirk, Michael Kuskowski. (2009) Changes in Vitamin E Prescribing for Alzheimer Patients. American Journal of Geriatric Psychiatry 17:7, 621-624
    CrossRef

62. 62

    Robert G Fassett, Jeff S Coombes. (2009) Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiology 5:4, 333-342
    CrossRef

63. 63

    GLEN SUMNER, OMID SALEHIAN, QILONG YI, JEFF HEALEY, JAMES MATHEW, KHALID AL-MERRI, KHALED AL-NEMER, J.F.E. MANN, GILLES DAGENAIS, EVA LONN. (2009) The Prognostic Significance of Bundle Branch Block in High-Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial. Journal of Cardiovascular Electrophysiology 20:7, 781-787
    CrossRef

64. 64

    Achuthan Raghavamenon, Mahdi Garelnabi, Sainath Babu, Alex Aldrich, Dmitry Litvinov, Sampath Parthasarathy. (2009) α-Tocopherol Is Ineffective in Preventing the Decomposition of Preformed Lipid Peroxides and May Promote the Accumulation of Toxic Aldehydes: A Potential Explanation for the Failure of Antioxidants to Affect Human Atherosclerosis. Antioxidants & Redox Signaling 11:6, 1237-1248
    CrossRef

65. 65

    M. J. Thomson, M. P. Frenneaux, J. C. Kaski. (2009) Antioxidant treatment for heart failure: friend or foe?. QJM 102:5, 305-310
    CrossRef

66. 66

    S. Honarbakhsh, M. Schachter. (2009) Vitamins and cardiovascular disease. British Journal of Nutrition 101:08, 1113
    CrossRef

67. 67

    Niki Katsiki, Christos Manes. (2009) Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. Clinical Nutrition 28:1, 3-9
    CrossRef

68. 68

    Andrew P Levy. (2009) Modification of HDL structure and function in individuals with diabetes and the haptoglobin 2-2 genotype. Clinical Lipidology 4:1, 5-8
    CrossRef

69. 69

    Martha Verghese, Rajitha Sunkara, Louis Shackelford, Lloyd Walker. 2009. Lycopene and Cardiovascular Diseases. , 243-271.
    CrossRef

70. 70

    2009. Vitamins and Minerals as Functional Ingredients. , 197-236.
    CrossRef

71. 71

    Christine Dalgård, Flemming Nielsen, Jason D. Morrow, Henrik Enghusen-Poulsen, Torbjörn Jonung, Mogens Hørder, Moniek P. M. de Maat. (2009) Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. British Journal of Nutrition 101:02, 263
    CrossRef

72. 72

    M. Hori, K. Nishida. (2008) Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovascular Research 81:3, 457-464
    CrossRef

73. 73

    Stephen J. Nicholls. (2008) The Complex Intersection of Inflammation and Oxidation. Journal of the American College of Cardiology 52:17, 1379-1380
    CrossRef

74. 74

    Shinn-Jong Jiang, Lee Ann Campbell, Mark W. Berry, Michael E. Rosenfeld, Cho-Chou Kuo. (2008) Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis. Microbes and Infection 10:12-13, 1393-1397
    CrossRef

75. 75

    Michelle Le Brocq, Stephen J. Leslie, Philip Milliken, Ian L. Megson. (2008) Endothelial Dysfunction: From Molecular Mechanisms to Measurement, Clinical Implications, and Therapeutic Opportunities. Antioxidants & Redox Signaling 10:9, 1631-1674
    CrossRef

76. 76

    Barry A Franklin, Justin E Trivax, Thomas E Vanhecke. (2008) New insights in preventive cardiology and cardiac rehabilitation. Current Opinion in Cardiology 23:5, 477-486
    CrossRef

77. 77

    Vijaya Juturu. 2008. Tocopherol and Tocotrienols. , 223-235.
    CrossRef

78. 78

    Stacey J. Bell, Gregory T. Grochoski. (2008) How Safe is Vitamin E Supplementation?. Critical Reviews in Food Science and Nutrition 48:8, 760-774
    CrossRef

79. 79

    M. Hacquebard, M. Vandenbranden, W. J. Malaisse, J. M. Ruysschaert, R. J. Deckelbaum, Y. A. Carpentier. (2008) Vitamin E Transfer from Lipid Emulsions to Plasma Lipoproteins: Mediation by Multiple Mechanisms. Lipids 43:7, 663-671
    CrossRef

80. 80

    Laura Franzini, Diego Ardigò, Ivana Zavaroni. (2008) Dietary antioxidants and glucose metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 11:4, 471-476
    CrossRef

81. 81

    Rebecca L. Charles, Philip Eaton. (2008) Redox signalling in cardiovascular disease. PROTEOMICS – CLINICAL APPLICATIONS 2:6, 823-836
    CrossRef

82. 82

    Maqsood M. Elahi, Michael Yii, Bashir M. Matata. (2008) Significance of Oxidants and Inflammatory Mediators in Blood of Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 22:3, 455-467
    CrossRef

83. 83

    Anup Kale, Sonia Gawande, Swati Kotwal. (2008) Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytotherapy Research 22:5, 567-577
    CrossRef

84. 84

    C. Penna, D. Mancardi, S. Raimondo, S. Geuna, P. Pagliaro. (2008) The paradigm of postconditioning to protect the heart. Journal of Cellular and Molecular Medicine 12:2, 435-458
    CrossRef

85. 85

    Vera Bittner. (2008) Antioxidant Vitamins—No Benefit for CVD Prevention. Southern Medical Journal 101:4, 339-340
    CrossRef

86. 86

    Maret G Traber, Balz Frei, Joseph S Beckman. (2008) Vitamin E revisited: do new data validate benefits for chronic disease prevention?. Current Opinion in Internal Medicine 7:2, 155-163
    CrossRef

87. 87

    Linda Van Horn, Mikelle McCoin, Penny M. Kris-Etherton, Frances Burke, Jo Ann S. Carson, Catherine M. Champagne, Wahida Karmally, Geeta Sikand. (2008) The Evidence for Dietary Prevention and Treatment of Cardiovascular Disease. Journal of the American Dietetic Association 108:2, 287-331
    CrossRef

88. 88

    R. Cubbon, M. Kahn, M. T. Kearney. (2008) Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. International Journal of Clinical Practice 62:2, 287-299
    CrossRef

89. 89

    John P. A. Ioannidis, Hans-Olov Adami. (2008) Nested Randomized Trials in Large Cohorts and Biobanks. Epidemiology 19:1, 75-82
    CrossRef

90. 90

    Marci Goldstein Adams, Stacie Geller, Laura Studee. 2007. Menopause and Midlife. .
    CrossRef

91. 91

    Caroline Moats, Eric B. Rimm. (2007) Vitamin intake and risk of coronary disease: Observation versus intervention. Current Atherosclerosis Reports 9:6, 508-514
    CrossRef

92. 92

    Feral Temelli, Marleny Saldaña, Paul Moquin, Mei Sun. 2007. Supercritical Fluid Extraction of Specialty Oils. , 51-101.
    CrossRef

93. 93

    Regina Brigelius-Flohé. (2007) Adverse effects of vitamin E by induction of drug metabolism. Genes & Nutrition 2:3, 249-256
    CrossRef

94. 94

    Andrew P Levy, Shany Blum. (2007) Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Review of Cardiovascular Therapy 5:6, 1105-1111
    CrossRef

95. 95

    Tracie L. Miller, Daniela Neri, Jason Extein, Gabriel Somarriba, Nancy Strickman-Stein. (2007) Nutrition in pediatric cardiomyopathy. Progress in Pediatric Cardiology 24:1, 59-71
    CrossRef

96. 96

    Raymond A. Firestone. (2007) Studies with vitamin E and β-carotene as single agents do not prove lack of benefit. British Journal of Nutrition 98:05,
    CrossRef

97. 97

    Erkan Tuncay, A. Aytac Seymen, Evrim Tanriverdi, Nazmi Yaras, Berivan Tandogan, N. Nuray Ulusu, Belma Turan. (2007) Gender related differential effects of Omega-3E treatment on diabetes-induced left ventricular dysfunction. Molecular and Cellular Biochemistry 304:1-2, 255-263
    CrossRef

98. 98

    Pierre Van Antwerpen, Jean Néve, Patrick Moreau, Karim Zouaoui Boudjeltia, Michel Vanhaeverbeek, Martine Prévost, Sajida Babar, Ilham Legssyer, Nicole Moguilevsky, Jean Ducobu. (2007) Probucol Does not Inhibit Myeloperoxidase-Dependent Low-Density Lipoprotein Oxidation as a Potent Protective Effect in Atherosclerosis. Journal of Cardiovascular Pharmacology 50:3, 350-351
    CrossRef

99. 99

    Gloria V. López, Fabiana Blanco, Paola Hernández, Ana Ferreira, Oscar E. Piro, Carlos Batthyány, Mercedes González, Homero Rubbo, Hugo Cerecetto. (2007) Second generation of α-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization. Bioorganic & Medicinal Chemistry 15:18, 6262-6272
    CrossRef

100. 100

     Ingrid Hickman, Graeme Macdonald. (2007) Is vitamin E beneficial in chronic liver disease?. Hepatology 46:2, 288-290
     CrossRef

101. 101

     L Feldman, S Efrati, E Eviatar, R Abramsohn, I Yarovoy, E Gersch, Z Averbukh, J Weissgarten. (2007) Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney International 72:3, 359-363
     CrossRef

102. 102

     Ginger Milne, Ling Gao, Joshua Brooks, Jason Morrow. 2007. The Role of Oxidative Stress in Diseases Associated with Overweight and Obesity. , 33-46.
     CrossRef

103. 103

     Subramaniam Pennathur, Jay W. Heinecke. (2007) Mechanisms for Oxidative Stress in Diabetic Cardiovascular Disease. Antioxidants & Redox Signaling 9:7, 955-969
     CrossRef

104. 104

     Stephen Scheidt, Nanette K. Wenger, Michael A. Weber. (2007) Patient Selection, Statistical Presumption, and Uncertainty of Outcomes. The American Journal of Geriatric Cardiology 16:4, 213-215
     CrossRef

105. 105

     J-C Dussaule, C Chatziantoniou. (2007) Reversal of renal disease: is it enough to inhibit the action of angiotensin II?. Cell Death and Differentiation 14:7, 1343-1349
     CrossRef

106. 106

     Holly C Williams, Kathy K Griendling. (2007) NADPH Oxidase Inhibitors: New Antihypertensive Agents?. Journal of Cardiovascular Pharmacology 50:1, 9-16
     CrossRef

107. 107

     Mika J. Thomson, Valentina Puntmann, Juan-Carlos Kaski. (2007) Atherosclerosis and Oxidant Stress: The End of the Road for Antioxidant Vitamin Treatment?. Cardiovascular Drugs and Therapy 21:3, 195-210
     CrossRef

108. 108

     Ramón Rodrigo, Cristián Guichard, Roberto Charles. (2007) Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundamental & Clinical Pharmacology 21:2, 111-127
     CrossRef

109. 109

     Adeline L.Y. Tan, Josephine M. Forbes, Mark E. Cooper. (2007) AGE, RAGE, and ROS in Diabetic Nephropathy. Seminars in Nephrology 27:2, 130-143
     CrossRef

110. 110

     Susie Yim, Atul Malhotra, Aristidis Veves. (2007) Antioxidants and CVD in diabetes: Where do we stand now?. Current Diabetes Reports 7:1, 8-13
     CrossRef

111. 111

     Wayne H. F. Sutherland, Patrick J. Manning, Robert J. Walker, Sylvia A. de Jong, Anne R. Ryalls, Elizabeth A. Berry. (2007) Vitamin E Supplementation and Plasma 8-Isoprostane and Adiponectin in Overweight Subjects*. Obesity 15:2, 386-391
     CrossRef

112. 112

     Kathleen M. Hayden, Kathleen A. Welsh-Bohmer, Heidi J. Wengreen, Peter P. Zandi, Constantine G. Lyketsos, John C.S. Breitner. (2007) Risk of Mortality with Vitamin E Supplements: The Cache County Study. The American Journal of Medicine 120:2, 180-184
     CrossRef

113. 113

     Christine A. Northrop-Clewes, David I. Thurnham. (2007) Monitoring micronutrients in cigarette smokers. Clinica Chimica Acta 377:1-2, 14-38
     CrossRef

114. 114

     Elizabeth Tran, Barbara Demmig-Adams. (2007) Vitamins and minerals: powerful medicine or potent toxins?. Nutrition & Food Science 37:1, 50-60
     CrossRef

115. 115

     Jeffrey Knox, Barak Gaster. (2007) Dietary Supplements for The Prevention and Treatment of Coronary Artery Disease. The Journal of Alternative and Complementary Medicine 13:1, 83-96
     CrossRef

116. 116

     Graziano Riccioni, Tonino Bucciarelli, Barbara Mancini, Carmine Di Ilio, Valerie Capra, Nicolantonio D’Orazio. (2007) The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. Expert Opinion on Investigational Drugs 16:1, 25-32
     CrossRef

117. 117

     Craig D. Rubin. (2006) The Primary Care of Alzheimer Disease. The American Journal of the Medical Sciences 332:6, 314-333
     CrossRef

118. 118

     Mohamed Alaa Thabet, James C. M. Chan. (2006) Vitamin E in renal therapeutic regimens. Pediatric Nephrology 21:12, 1790-1801
     CrossRef

119. 119

     Pietro Galassetti, Andria Pontello. (2006) Dietary effects on oxidation of low-density lipoprotein and atherogenesis. Current Atherosclerosis Reports 8:6, 523-529
     CrossRef

120. 120

     Andrew P. Levy. (2006) Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: Mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacology & Therapeutics 112:2, 501-512
     CrossRef

121. 121

     Yumei Cao, Jun Zhang, Penny M. Kris-Etherton. 2006. Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease. , 79-146.
     CrossRef

122. 122

     Nosratola D Vaziri, Bernardo Rodríguez-Iturbe. (2006) Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clinical Practice Nephrology 2:10, 582-593
     CrossRef

123. 123

     Ioanna Andreadou, Efstathios K. Iliodromitis, Konstantinos Tsovolas, Ioanna-Katerina Aggeli, Anastasia Zoga, Catherine Gaitanaki, Ioannis A. Paraskevaidis, Sophia L. Markantonis, Isidoros Beis, Dimitrios Th. Kremastinos. (2006) Acute administration of vitamin E triggers preconditioning via KATP channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radical Biology and Medicine 41:7, 1092-1099
     CrossRef

124. 124

     Hendrik Buikema. (2006) Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Review of Cardiovascular Therapy 4:5, 631-647
     CrossRef

125. 125

     Jia Liu, Kambiz Kalantarinia, Mitchell H. Rosner. (2006) Management of Lipid Abnormalities Associated with End-Stage Renal Disease. Seminars In Dialysis 19:5, 391-401
     CrossRef

126. 126

     Matthew A. Roberts, David L. Hare, Sujiva Ratnaike, Francesco L. Ierino. (2006) Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. American Journal of Kidney Diseases 48:3, 341-360
     CrossRef

127. 127

     Vanessa P.M. van Empel, Anne T. Bertrand, Ralph J. van Oort, Roel van der Nagel, Markus Engelen, Harold V. van Rijen, Pieter A. Doevendans, Harry J. Crijns, Susan L. Ackerman, Wim Sluiter, Leon J. De Windt. (2006) EUK-8, a Superoxide Dismutase and Catalase Mimetic, Reduces Cardiac Oxidative Stress and Ameliorates Pressure Overload-Induced Heart Failure in the Harlequin Mouse Mutant. Journal of the American College of Cardiology 48:4, 824-832
     CrossRef

128. 128

     Pietro Minuz, Cristiano Fava, Luciano Cominacini. (2006) Oxidative stress, antioxidants, and vascular damage. British Journal of Clinical Pharmacology 61:6, 774-777
     CrossRef

129. 129

     Dianna Magliano, John McNeil, Pauline Branley, Louise Shiel, Lisa Demos, Rory Wolfe, Dimitra Kotsopoulos, Barry McGrath. (2006) The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. European Journal of Cardiovascular Prevention & Rehabilitation 13:3, 341-347
     CrossRef

130. 130

     Roberto Marchioli, Giacomo Levantesi, Alejandro Macchia, Rosa Maria Marfisi, Gian Luigi Nicolosi, Luigi Tavazzi, Gianni Tognoni, Franco Valagussa. (2006) Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine 7:5, 347-350
     CrossRef

131. 131

     Klaus K Witte, Andrew L Clark. (2006) Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Failure Reviews 11:1, 65-74
     CrossRef

132. 132

     Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Journal of the American College of Cardiology 47:6, e1-e192
     CrossRef

133. 133

     Kieren J. Mather, Alain D. Baron. 2006. Vascular Dysfunction and Obesity. , 93-120.
     CrossRef

134. 134

     Marc L. Allard, Khursheed N. Jeejeebhoy, Michael J. Sole. (2006) The management of conditioned nutritional requirements in heart failure. Heart Failure Reviews 11:1, 75-82
     CrossRef

135. 135

     Ingo Schulte, Huseyin Bektas, J??rgen Klempnauer, J??rgen Borlak. (2006) Vitamin E in Heart Transplantation: Effects on Cardiac Gene Expression. Transplantation 81:5, 736-745
     CrossRef

136. 136

     Marietta Charakida, John E. Deanfield, Julian P. J. Halcox. (2006) The role of nitric oxide in early atherosclerosis. European Journal of Clinical Pharmacology 62:S1, 69-78
     CrossRef

137. 137

     Cathy Nonas, Bantwal Suresh Baliga, Zachary Bloomgarden. 2006. Medical Nutrition Therapy For Patients With Type-2 Diabetes. , 81-104.
     CrossRef

138. 138

     Jan K. Damås, Pål Aukrust. (2006) Systemic markers of inflammation – are they useful predictive tools in coronary artery disease?. Scandinavian Cardiovascular Journal 40:5, 262-266
     CrossRef

139. 139

     Sven Wassmann, Kerstin Wassmann, Georg Nickenig. (2006) Regulation of antioxidant and oxidant enzymes in vascular cells and implications for vascular disease. Current Hypertension Reports 8:1, 69-78
     CrossRef

140. 140

     Ji Hye Suk, Mi Kyung Kim, Jae Won Ju, Ji Sook Han, Jeong Hyun Park. (2006) The Effect of Green Tea Polyphenol on Plasma Glucose, Lipid Levels and Antioxidant Systems in Type 2 Diabetic Patients. The Journal of Korean Diabetes Association 30:3, 217
     CrossRef

141. 141

     Costas Hanjis, William H. Frishman, Robert G. Lerner. (2006) Aspirin Resistance. Cardiology in Review 14:1, 18-25
     CrossRef

142. 142

     Lindsie A. Robertson, Anna J. Kim, Geoff H. Werstuck. (2006) Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3This paper is one of a selection of papers published in this Special Issue, entitled Young Investigator's Forum.. Canadian Journal of Physiology and Pharmacology 84:1, 39-48
     CrossRef

143. 143

     Bo Hyun Kim, Seok Man Son. (2006) Mechanism of Developing Diabetic Vascular Complication by Oxidative Stress. Journal of Korean Endocrine Society 21:6, 448
     CrossRef

144. 144

     Kenichi Tsujita, Hideki Shimomura, Koichi Kaikita, Hiroaki Kawano, Jun Hokamaki, Yasuhiro Nagayoshi, Takuro Yamashita, Masaya Fukuda, Yoshinori Nakamura, Tomohiro Sakamoto, Michihiro Yoshimura, Hisao Ogawa. (2006) Long-Term Efficacy of Edaravone in Patients With Acute Myocardial Infarction. Circulation Journal 70:7, 832-837
     CrossRef

145. 145

     Norito Kawakami, Akizumi Tsutsumi, Takashi Haratani, Fumio Kobayashi, Masao Ishizaki, Takeshi Hayashi, Osamu Fujita, Yoshiharu Aizawa, Shogo Miyazaki, Hisanori Hiro, Takeshi Masumoto, Shuji Hashimoto, Shunichi Araki. (2006) Job Strain, Worksite Support, and Nutrient Intake among Employed Japanese Men and Women. Journal of Epidemiology 16:2, 79-89
     CrossRef

146. 146

     Harlan Jones, Robert Carter. 2005. The Vascular Biology of Atherosclerosis. , 61-84.
     CrossRef

147. 147

     Carol M. Baldwin, Richard R. Bootzin, Dawn C. Schwenke, Stuart F. Quan. (2005) Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. Sleep Medicine Reviews 9:6, 459-476
     CrossRef

148. 148

     Giovanni Maria Puddu, Eleonora Cravero, Giorgia Arnone, Antonio Muscari, Paolo Puddu. (2005) Molecular aspects of atherogenesis: new insights and unsolved questions. Journal of Biomedical Science 12:6, 839-853
     CrossRef

149. 149

     Leo G. Kevin, Enis Novalija, David F. Stowe. (2005) Reactive Oxygen Species as Mediators of Cardiac Injury and Protection: The Relevance to Anesthesia Practice. Anesthesia & Analgesia 101:5, 1275-1287
     CrossRef

150. 150

     L Seppo, T Lähteenmäki, M J Tikkanen, H Vanhanen, R Korpela, H Vapaatalo. (2005) Effects of vitamin E on the toxicity of oxidized LDL on endothelial cells in vitro in smokers vs nonsmokers on diets rich in fish. European Journal of Clinical Nutrition 59:11, 1282-1290
     CrossRef

151. 151

     Gordon T McInnes. (2005) Antioxidants and hypertension: another false dawn?. Journal of Hypertension 23:11, 1963-1966
     CrossRef

152. 152

     Pål Aukrust, Arne Yndestad, Torgun Wæhre, Lars Gullestad, Bente Halvorsen, Jan Kristian Damås. (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy 3:6, 1111-1124
     CrossRef

153. 153

     Angela Mastaloudis, Maret Traber. 2005. Vitamin E. , 183-200.
     CrossRef

154. 154

     Erik S. Musiek, Huiyong Yin, Ginger L. Milne, Jason D. Morrow. (2005) Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40:10, 987-994
     CrossRef

155. 155

     Gloria V. López, Carlos Batthyány, Fabiana Blanco, Horacio Botti, Andrés Trostchansky, Eduardo Migliaro, Rafael Radi, Mercedes González, Hugo Cerecetto, Homero Rubbo. (2005) Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs. Bioorganic & Medicinal Chemistry 13:20, 5787-5796
     CrossRef

156. 156

     H. Gohlke. (2005) Ernährung. Zeitschrift für Kardiologie 94:S3, iii15-iii21
     CrossRef

157. 157

     Pål Aukrust, Arne Yndestad, Camilla Smith, Wiggo J Sandberg, Thor Ueland, Torgun Wæhre, Bente Halvorsen, Lars Gullestad, Jan Kristian Damås. (2005) Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opinion on Pharmacotherapy 6:13, 2169-2180
     CrossRef

158. 158

     Shoji Kimura, Guo-Xing Zhang, Akira Nishiyama, Yukiko Nagai, Toshitaka Nakagawa, Hiroshi Miyanaka, Yoshihide Fujisawa, Akira Miyatake, Tsubasa Nagai, Masaaki Tokuda, Youichi Abe. (2005) D-allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats. Journal of Hypertension 23:10, 1887-1894
     CrossRef

159. 159

     John H.K. Vogel, Steven F. Bolling, Rebecca B. Costello, Erminia M. Guarneri, Mitchell W. Krucoff, John C. Longhurst, Brian Olshansky, Kenneth R. Pelletier, Cynthia M. Tracy, Robert A. Vogel, Robert A. Vogel, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Bruce R. Brodie, Cindy L. Grines, Peter G. Danias, Gabriel Gregoratos, Mark A. Hlatky, Judith S. Hochman, Sanjiv Kaul, Robert C. Lichtenberg, Jonathan R. Lindner, Robert A. O’Rourke, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, Cynthia M. Tracy, William L. Winters. (2005) Integrating Complementary Medicine Into Cardiovascular Medicine. Journal of the American College of Cardiology 46:1, 184-221
     CrossRef

160. 160

     R. Marchioli, G. Levantesi, A. Macchia, A.P. Maggioni, R.M. Marfisi, M.G. Silletta, L. Tavazzi, G. Tognoni, F. Valagussa. (2005) Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology 206:2, 117-128
     CrossRef

161. 161

     A. Barceló, F. Barbé. (2005) Estrés oxidativo y síndrome de apneas-hipopneas del sueño. Archivos de Bronconeumología 41:7, 393-399
     CrossRef

162. 162

     Xiaobing Guo, Harjot K Saini, Jingwei Wang, Suresh K Gupta, Ramesh K Goyal, Naranjan S Dhalla. (2005) Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system. Expert Review of Cardiovascular Therapy 3:4, 717-732
     CrossRef

163. 163

     William D. Fraser, Francois Audibert, Emmanuel Bujold, Line Leduc, Hairong Xu, Michel Boulvain, Pierre Julien. (2005) The vitamin E debate: implications for ongoing trials of pre-eclampsia prevention. BJOG: An International Journal of Obstetrics and Gynaecology 112:6, 684-688
     CrossRef

164. 164

     Kanwaljit Mahal, Javier Hernandez, Joseph W. Basler, Ian M. Thompson. (2005) What’s new in the field of prostate cancer chemoprevention?. Current Urology Reports 6:3, 177-182
     CrossRef

165. 165

     S. H. A. DIEPEVEEN, G. W. H. E. VERHOEVEN, J. VAN DER PALEN, L. D. DIKKESCHEI, L. J. TITS, G. KOLSTERS, J. J. G. OFFERMAN, H. J. G. BILO, A. F. H. STALENHOEF. (2005) Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Journal of Internal Medicine 257:5, 438-445
     CrossRef

166. 166

     M. Soccio, E. Toniato, V. Evangelista, M. Carluccio, R. De Caterina. (2005) Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. European Journal of Clinical Investigation 35:5, 305-314
     CrossRef

167. 167

     S. A. Marsh, B. K. Pat, G. C. Gobe, J. S. Coombes. (2005) Evidence for a non-antioxidant, dose-dependent role of α -lipoic acid in caspase-3 and ERK2 activation in endothelial cells. Apoptosis 10:3, 657-665
     CrossRef

168. 168

     Hannah Bartlett, Frank Eperjesi. (2005) Possible contraindications and adverse reactions associated with the use of ocular nutritional supplements. Ophthalmic and Physiological Optics 25:3, 179-194
     CrossRef

169. 169

     Robert C Kaplan, Clyde Schechter. (2005) Cost implications of new evidence on prevention of cardiovascular disease. Expert Review of Pharmacoeconomics & Outcomes Research 5:2, 183-192
     CrossRef

170. 170

     Veronica Verde, Gabriella Leonarduzzi, Barbara Sottero, Giuseppe Poli. 2005. Oxidized Products of Cholesterol. .
     CrossRef

171. 171

     Mirjam Hacquebard, Yvon A Carpentier. (2005) Vitamin E: absorption, plasma transport and cell uptake. Current Opinion in Clinical Nutrition and Metabolic Care 8:2, 133-138
     CrossRef

172. 172

     Frank J. Giordano. (2005) Oxygen, oxidative stress, hypoxia, and heart failure. Journal of Clinical Investigation 115:3, 500-508
     CrossRef

173. 173

     Yizhen Xu, Zhiheng He, George L. King. (2005) Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. Current Diabetes Reports 5:2, 91-97
     CrossRef

174. 174

     Angelo Azzi, Regina Brigelius-Floh, Frank Kelly, John K. Lodge, Nesrin zer, Lester Packer, Helmut Sies. (2005) On the opinion of the European Commission ?Scientific Committee on Food? regarding the tolerable upper intake level of vitamin E (2003). European Journal of Nutrition 44:1, 60-62
     CrossRef

175. 175

     Mark A Moyad. (2005) Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part II. Current Opinion in Urology 15:1, 7-12
     CrossRef

176. 176

     Georgia Antoniadi, Theodoros Eleftheriadis, Vasilios Liakopoulos, Eleni Kakasi, Georgios Vayonas, Alexandros Kortsaris, Vasilios Vargemezis. (2005) Effect of 1-Year Oral α-Tocopherol Administration on Anticardiolipin Antibodies in Hemodialysis Patients. Renal Failure 27:2, 193-198
     CrossRef

177. 177

     Hui Sui, Wen Wang, Pei‐He Wang, Li‐Sheng Liu. (2005) Effect of glutathione peroxidase mimic ebselen (PZ51) on endothelium and vascular structure of stroke‐prone spontaneously hypertensive rats. Blood Pressure 14:6, 366-372
     CrossRef

178. 178

     Jean-Claude Tardif. (2005) Antioxidants and atherosclerosis: Emerging drug therapies. Current Atherosclerosis Reports 7:1, 71-77
     CrossRef

179. 179

     Paolo Puddu, Giovanni M. Puddu, Livia Galletti, Eleonora Cravero, Antonio Muscari. (2005) Mitochondrial Dysfunction as an Initiating Event in Atherogenesis: A Plausible Hypothesis. Cardiology 103:3, 137-141
     CrossRef

180. 180

     Norberto Andaluz, Mario Zuccarello. (2005) Place of Drug Therapy in the Treatment of Carotid Stenosis. CNS Drugs 19:7, 597-622
     CrossRef

181. 181

     Tomomi IDE, Hiroyuki TSUTSUI. (2005) New strategy of cardiovascular disease by redox regulation. Japanese Journal of Thrombosis and Hemostasis 16:4, 365-371
     CrossRef

182. 182

     Joseph M Li, Kenneth J Mukamal. (2004) An update on alcohol and atherosclerosis. Current Opinion in Lipidology 15:6, 673-680
     CrossRef

183. 183

     MOHSEN MEYDANI. (2004) Vitamin E Modulation of Cardiovascular Disease. Annals of the New York Academy of Sciences 1031:1, 271-279
     CrossRef

184. 184

     Johannes F.E. Mann, Qi-Long Yi, Hertzel C. Gerstein. (2004) Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney International 66:s92, S59-S62
     CrossRef

185. 185

     Phyllis E. Bowen, Gayatri Borthakur. (2004) Postprandial lipid oxidation and cardiovascular disease risk. Current Atherosclerosis Reports 6:6, 477-484
     CrossRef

186. 186

     Mark A. Moyad. (2004) Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: Part I. Urologic Oncology: Seminars and Original Investigations 22:6, 466-471
     CrossRef

187. 187

     Martin Tepel, Walter Zidek. (2004) N-Acetylcysteine in nephrology; contrast nephropathy and beyond. Current Opinion in Nephrology and Hypertension 13:6, 649-654
     CrossRef

188. 188

     Rajiv Gupta, Yochai Birnbaum, Barry F. Uretsky. (2004) The renal patient with coronary artery disease. Journal of the American College of Cardiology 44:7, 1343-1353
     CrossRef

189. 189

     R. M. Touyz, E. L. Schiffrin. (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochemistry and Cell Biology 122:4, 339-352
     CrossRef

190. 190

     Melanie L. Blackhall, Jeff S. Coombes, Rob Fassett. (2004) The Relationship Between Antioxidant Supplements and Oxidative Stress in Renal Transplant Recipients: A Review. ASAIO Journal 50:5, 451-457
     CrossRef

191. 191

     Paresh Dandona, Sandeep Dhindsa, Ahmad Aljada, Ajay Chaudhuri. (2004) Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. Metabolic Syndrome and Related Disorders 2:3, 155-159
     CrossRef

192. 192

     Behzad Molavi, Jawahar L Mehta. (2004) Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Current Opinion in Cardiology 19:5, 488-493
     CrossRef

193. 193

     R. L. Prentice, W. C. Willett, P. Greenwald, D. Alberts, L. Bernstein, N. F. Boyd, T. Byers, S. K. Clinton, G. Fraser, L. Freedman, D. Hunter, V. Kipnis, L. N. Kolonel, B. S. Kristal, A. Kristal, J. W. Lampe, A. McTiernan, J. Milner, R. E. Patterson, J. D. Potter, E. Riboli, A. Schatzkin, A. Yates, E. Yetley. (2004) Nutrition and Physical Activity and Chronic Disease Prevention: Research Strategies and Recommendations. JNCI Journal of the National Cancer Institute 96:17, 1276-1287
     CrossRef

194. 194

     MARTIJN B. KATAN, NICOLE M. ROOS. (2004) Promises and Problems of Functional Foods. Critical Reviews in Food Science and Nutrition 44:5, 369-377
     CrossRef

195. 195

     G.T. Chew. (2004) Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. QJM 97:8, 537-548
     CrossRef

196. 196

     Manfred Eggersdorfer, David Burdick, Regina Goralczyk, Daniel Raederstorff, Christoph Riegger, Wolfgang Schalch, Elisabeth Stöcklin, Peter Weber, Werner Bonrath. 2004. Nutraceuticals. .
     CrossRef

197. 197

     Seok Man Son, Matthew K. Whalin, David G. Harrison, W. Robert Taylor, Kathy K. Griendling. (2004) Oxidative stress and diabetic vascular complications. Current Diabetes Reports 4:4, 247-252
     CrossRef

198. 198

     John Concato. (2004) Observationalversus experimental studies: What’s the evidence for a hierarchy?. NeuroRX 1:3, 341-347
     CrossRef

199. 199

     Hannah Bartlett, Frank Eperjesi. (2004) An ideal ocular nutritional supplement?*. Ophthalmic and Physiological Optics 24:4, 339-349
     CrossRef

200. 200

     M. Paola Pellegrini, David E. Newby, Neil R. Johnston, Simon Maxwell, David J. Webb. (2004) Vitamin C Has No Effect on Endothelium-Dependent Vasomotion and Acute Endogenous Fibrinolysis in Healthy Smokers. Journal of Cardiovascular Pharmacology 44:1, 117-124
     CrossRef

201. 201

     A. D. Dangour, V. L. Sibson, A. E. Fletcher. (2004) Hormones and Supplements: Do They Work?: Micronutrient Supplementation in Later Life: Limited Evidence for Benefit. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:7, B659-B673
     CrossRef

202. 202

     S. J. Wigg, M. Tare, J. Forbes, M. E. Cooper, M. C. Thomas, H. A. Coleman, H. C. Parkington, R. C. O’Brien. (2004) Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C-β in mesenteric artery and ameliorates wall stiffness in femoral artery of Wistar rats. Diabetologia 47:6, 1038-1046
     CrossRef

203. 203

     Kanwaljit Mahal, Javier Hernandez, Joseph W. Basler, Ian M. Thompson. (2004) What’s new in the field of prostate cancer chemoprevention?. Current Oncology Reports 6:3, 237-242
     CrossRef

204. 204

     Kenneth A Hoekstra, David V Godin, Kimberly M Cheng. (2004) Protective role of heme oxygenase in the blood vessel wall during atherogenesis. Biochemistry and Cell Biology 82:3, 351-359
     CrossRef

205. 205

     Eduardo Shahar, Gamal Hassoun, Shimon Pollack. (2004) Effect of vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. Annals of Allergy, Asthma & Immunology 92:6, 654-658
     CrossRef

206. 206

     S Vincent, M Gerber, MC Bernard, C Defoort, A Loundou, H Portugal, R Planells, I Juhan-Vague, P Charpiot, P Grolier, MJ Amiot-Carlin, P Vague, D Lairon. (2004) The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants. Public Health Nutrition 7:04,
     CrossRef

207. 207

     Ronald Eitenmiller. 2004. Nutrition and Health Implications of Vitamin E. , 39-88.
     CrossRef

208. 208

     SA Stanner, J Hughes, CNM Kelly, J Buttriss. (2004) A review of the epidemiological evidence for the ‘antioxidant hypothesis’. Public Health Nutrition 7:03,
     CrossRef

209. 209

     Amanda James Wilburn, Deborah S. King, James Glisson, Robin W. Rockhold, Marion R. Wofford. (2004) The Natural Treatment of Hypertension. The Journal of Clinical Hypertension 6:5, 242-248
     CrossRef

210. 210

     Ligia F. Gomes, André F. Alves, Alex Sevanian, Clóvis de Araújo Peres, Maysa S. Cendoroglo, Clineu de Mello-Almada Fo., Lara M. Quirino, Luiz R. Ramos, Virgínia B.C. Junqueira. (2004) Role of β ₂ -Glycoprotein I, LDL-, and Antioxidant Levels in Hypercholesterolemic Elderly Subjects. Antioxidants & Redox Signaling 6:2, 237-244
     CrossRef

211. 211

     P. Strazzullo, L. Scalfi, F. Branca, G. Cairella, F. Garbagnati, A. Siani, G. Barba, P. Rubba, G. Mancia. (2004) Nutrition and prevention of ischemic stroke: present knowledge, limitations and future perspectives. Nutrition, Metabolism and Cardiovascular Diseases 14:2, 97-114
     CrossRef

212. 212

     Johannes F.E. Mann, Eva M. Lonn, Qilong Yi, Hertzel C. Gerstein, Byron J. Hoogwerf, Janice Pogue, Jackie Bosch, Gilles R. Dagenais, Salim Yusuf, . (2004) Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International 65:4, 1375-1380
     CrossRef

213. 213

     Paul G. Shekelle, Sally C. Morton, Lara K. Jungvig, Jay Udani, Myles Spar, Wenli Tu, Marika J. Suttorp, Ian Coulter, Sydne J. Newberry, Mary Hardy. (2004) Effect of Supplemental Vitamin E for the Prevention and Treatment of Cardiovascular Disease. Journal of General Internal Medicine 19:4, 380-389
     CrossRef

214. 214

     Ross T Murphy, J.Brendan Foley, Marie-Teresa Tome, Niall T Mulvihill, Anne Murphy, Nuala McCarroll, Peter Crean, Micheal J Walsh. (2004) Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. Free Radical Biology and Medicine 36:8, 959-965
     CrossRef

215. 215

     Peter Sanderson, Margreet Olthof, Robert F. Grimble, Philip C. Calder, Bruce A. Griffin, Nicole M. de Roos, Jill J. F. Belch, David P. R. Muller, Joseph A. Vita. (2004) Dietary lipids and vascular function: UK Food Standards Agency workshop report. British Journal of Nutrition 91:03, 491
     CrossRef

216. 216

     Mina K. Chung. (2004) Vitamins, Supplements, Herbal Medicines, and Arrhythmias. Cardiology in Review 12:2, 73-84
     CrossRef

217. 217

     Pietro Vajro, Claudia Mandato, Adriana Franzese, Stefania Lucariello. (2004) More on vitamin E therapy. Hepatology 39:2, 569-569
     CrossRef

218. 218

     John J McNeil, Luba Robman, Gabriella Tikellis, Martha I Sinclair, Catherine A McCarty, Hugh R Taylor. (2004) Vitamin E supplementation and cataract. Ophthalmology 111:1, 75-84
     CrossRef

219. 219

     Adelina Munteanu, J.-M. Zingg, A. Azzi. (2004) Anti-atherosclerotic effects of vitamin E ? myth or reality?. Journal of Cellular and Molecular Medicine 8:1, 59-76
     CrossRef

220. 220

     Pietro Vajro, Claudia Mandato, Adriana Franzese, Edmondo Ciccimarra, Stefania Lucariello, Marcella Savoia, Grazia Capuano, Fiorella Migliaro. (2004) Vitamin E Treatment in Pediatric Obesity-Related Liver Disease: A Randomized Study. Journal of Pediatric Gastroenterology and Nutrition 38:1, 48-55
     CrossRef

221. 221

     Michael I Mackness, Paul N Durrington, Bharti Mackness. (2004) The Role of Paraoxonase 1 Activity in Cardiovascular Disease. American Journal of Cardiovascular Drugs 4:4, 211-217
     CrossRef

222. 222

     Ntei Abudu, James J Miller, Mohammed Attaelmannan, Stanley S Levinson. (2004) Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clinica Chimica Acta 339:1-2, 11-25
     CrossRef

223. 223

     W. l. Stone, G. Krishnaswamy, H. Yang. 2004. The role of fat-soluble nutrients and antioxidants in preventing heart disease. , 56-76.
     CrossRef

224. 224

     Dominique Bonnefont-Rousselot. (2004) The Role of Antioxidant Micronutrients in the Prevention of Diabetic Complications. Treatments in Endocrinology 3:1, 41-52
     CrossRef

225. 225

     Kenneth Hensley, Elaine J. Benaksas, Roberto Bolli, Philip Comp, Paula Grammas, Ladan Hamdheydari, Shenyun Mou, Quentin N. Pye, Marcus F. Stoddard, Gemma Wallis, Kelly S. Williamson, Melinda West, William J. Wechter, Robert A. Floyd. (2004) New perspectives on vitamin E: γ-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radical Biology and Medicine 36:1, 1-15
     CrossRef

226. 226

     John Concato. (2004) Observationalversus experimental studies: What’s the evidence for a hierarchy?. NeuroRX 1:3, 341
     CrossRef

227. 227

     Agostino Virdis, Lorenzo Ghiadoni, Guido Salvetti, Daniele Versari, Stefano Taddei, Antonio Salvetti. (2004) Endothelial Dysfunction, Vascular Damage and Clinical Events. High Blood Pressure & Cardiovascular Prevention 11:1, 15-27
     CrossRef

228. 228

     Shari S. Bassuk, Christine M. Albert, Nancy R. Cook, Elaine Zaharris, Jean G. MacFadyen, Eleanor Danielson, Martin Van Denburgh, Julie E. Buring, Joann E. Manson. (2004) The Women's Antioxidant Cardiovascular Study: Design and Baseline Characteristics of Participants. Journal of Women's Health 13:1, 99-117
     CrossRef

229. 229

     Marika Massaro, Maria Annunziata Carluccio, Maria Assunta Ancora, Egeria Scoditti, Raffaele De Caterina. 2003. Vasculoprotective Effects of Olive Oil. .
     CrossRef

230. 230

     Michel de Lorgeril, Patricia Salen. 2003. Dietary Prevention of CHD. .
     CrossRef

231. 231

     Carla Lopes, Susana Casal, Beatriz Oliveira, Henrique Barros. 2003. Retinol, Beta-Carotene, and Alpha-Tocopherol in Heart Disease. .
     CrossRef

232. 232

     Klaus Witte, Andrew Clark. 2003. Micronutrients and Cardiovascular Disease. .
     CrossRef

233. 233

     Eva Lonn, James Mathew, Janice Pogue, David Johnstone, Kola Danisa, Jackie Bosch, Michael Baird, Gilles Dagenais, Peter Sleight, Salim Yusuf. (2003) Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Cardiovascular Prevention & Rehabilitation 10:6, 420-428
     CrossRef

234. 234

     Sevgi Yardim-Akaydin, Yeşim Özkan, Ersin Özkan, Meral Torun, Bolkan Şimşek. (2003) The role of plasma thiol compounds and antioxidant vitamins in patients with cardiovascular diseases. Clinica Chimica Acta 338:1-2, 99-105
     CrossRef

235. 235

     Katherine E. Fayers, Michael H. Cummings, Kenneth M. Shaw, David W. Laight. (2003) Nitrate tolerance and the links with endothelial dysfunction and oxidative stress. British Journal of Clinical Pharmacology 56:6, 620-628
     CrossRef

236. 236

     Pedro Monteiro, Ana I Duarte, António Moreno, Lino M Gonçalves, Luı́s A Providência. (2003) Carvedilol improves energy production during acute global myocardial ischaemia. European Journal of Pharmacology 482:1-3, 245-253
     CrossRef

237. 237

     Norman I Krinsky. (2003) Human requirements for fat-soluble vitamins, and other things concerning these nutrients. Molecular Aspects of Medicine 24:6, 317-324
     CrossRef

238. 238

     Guy De Backer, Ettore Ambrosioni, Knut Broch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Guiseppe Mancia, Volkert Manger Cats, Kristina Orth-Gom??r, Joep Perk, Kalevi Py??r??l??, Jos?? L. Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood. (2003) European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 10:Supplement 1, S1-S78
     CrossRef

239. 239

     Michael E Widlansky, Noyan Gokce, John F Keaney, Joseph A Vita. (2003) The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology 42:7, 1149-1160
     CrossRef

240. 240

     Vanesa Esteban, Monica Ruperez, Juan Rodriguez Vita, Elsa Sanchez Lopez, Sergio Mezzano, Juan Jose Plaza, Jesus Egido, Marta Ruiz-Ortega. (2003) Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney International 64:s86, 33-38
     CrossRef

241. 241

     Joanne M. Upston, Leonard Kritharides, Roland Stocker. (2003) The role of vitamin E in atherosclerosis. Progress in Lipid Research 42:5, 405-422
     CrossRef

242. 242

     Sally H. Whitaker, Janet D. Pierce. (2003) Oxygen Free Radicals and the Disease Process. The Nurse Practitioner 28:8, 53-54
     CrossRef

243. 243

     Eberhard Schulz, John F. Keaney. (2003) Diabetes mellitus and endothelial dysfunction: a central role for oxidative stress. Current Opinion in Endocrinology & Diabetes 10:4, 237-244
     CrossRef

244. 244

     Marie-Luise Brennan, Stanley L. Hazen. (2003) Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Current Opinion in Lipidology 14:4, 353-359
     CrossRef

245. 245

     Omer L. Shedd, Marian C. Limacher. (2003) Prevention of cardiovascular disease in women. Current Treatment Options in Cardiovascular Medicine 5:4, 287-298
     CrossRef

246. 246

     Mariette Gerber. (2003) Biofactors in the Mediterranean Diet. Clinical Chemistry and Laboratory Medicine 41:8, 999-1004
     CrossRef

247. 247

     P. J. Devereaux, S. Yusuf. (2003) The evolution of the randomized controlled trial and its role in evidence-based decision making. Journal of Internal Medicine 254:2, 105-113
     CrossRef

248. 248

     Philip R. Liebson. (2003) ASAP and ANTIBIO. Preventive Cardiology 6:3, 166-170
     CrossRef

249. 249

     Maria C. G. Peluzio, Emir Miguel, Thaís C. Drumond, Giovana C. César, Helton C. Santiago, Mauro M. Teixeira, Enio C. Vieira, Rosa M. E. Arantes, Jacqueline I. Alvarez-Leite. (2003) Monocyte chemoattractant protein-1 involvement in the α-tocopherol-induced reduction of atherosclerotic lesions in apolipoprotein E knockout mice. British Journal of Nutrition 90:01, 3
     CrossRef

250. 250

     Francine Grodstein, Jennifer Chen, Susan E. Hankinson. (2003) Cataract Extraction and Cognitive Function in Older Women. Epidemiology 14:4, 493-497
     CrossRef

251. 251

     Rhian M Touyz. (2003) Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Review of Cardiovascular Therapy 1:1, 91-106
     CrossRef

252. 252

     Elliott J. F. Cantor, Enrico V. Mancini, Rishi Seth, Xing-Hai Yao, Thomas Netticadan. (2003) Oxidative stress and heart disease: Cardiac dysfunction, nutrition, and gene therapy. Current Hypertension Reports 5:3, 215-220
     CrossRef

253. 253

     Gary D Plotnick, Mary C Corretti, Robert A Vogel, Robert Hesslink, John A Wise. (2003) Effect of supplemental phytonutrients on impairment of the flow-mediated brachialartery vasoactivity after a single high-fat meal. Journal of the American College of Cardiology 41:10, 1744-1749
     CrossRef

254. 254

     Thomas G. Pickering. (2003) What Should We Advise Our Patients About Taking Antioxidants?. The Journal of Clinical Hypertension 5:3, 231-233
     CrossRef

255. 255

     S. B. Wheatcroft, I. L. Williams, A. M. Shah, M. T. Kearney. (2003) Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Medicine 20:4, 255-268
     CrossRef

256. 256

     Antonio M Gotto. (2003) Antioxidants, statins, and atherosclerosis. Journal of the American College of Cardiology 41:7, 1205-1210
     CrossRef

257. 257

     Uwe Rueckschloss, Nicole Duerrschmidt, Henning Morawietz. (2003) NADPH Oxidase in Endothelial Cells: Impact on Atherosclerosis. Antioxidants & Redox Signaling 5:2, 171-180
     CrossRef

258. 258

     Emma A. Meagherx. (2003) Treatment of Atherosclerosis in the New Millennium: Is There a Role for Vitamin E?. Preventive Cardiology 6:2, 85-90
     CrossRef

259. 259

     Philip A. MacCarthy, Ajay M. Shah. (2003) Oxidative stress and heart failure. Coronary Artery Disease 14:2, 109-113
     CrossRef

260. 260

     James M. Shikany, Ruth E. Patterson, Tanya Agurs-Collins, Garnet Anderson. (2003) Antioxidant supplement use in Women’s Health Initiative participants. Preventive Medicine 36:3, 379-387
     CrossRef

261. 261

     Ahmad Aljada. (2003) Endothelium, Inflammation, and Diabetes. Metabolic Syndrome and Related Disorders 1:1, 3-21
     CrossRef

262. 262

     Jay W. Heinecke. (2003) Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis?. Current Atherosclerosis Reports 5:2, 83-87
     CrossRef

263. 263

     Francois Madore. (2003) Uremia-Related Metabolic Cardiac Risk Factors in Chronic Kidney Disease. Seminars In Dialysis 16:2, 148-156
     CrossRef

264. 264

     Clemens Schacky. (2003) The role of omega-3 fatty acids in cardiovascular disease. Current Atherosclerosis Reports 5:2, 139-145
     CrossRef

265. 265

     Stephen J. Duffy, Joseph A. Vita. (2003) Effects of phenolics on vascular endothelial function. Current Opinion in Lipidology 14:1, 21-27
     CrossRef

266. 266

     JoAnn E. Manson, Shari S. Bassuk, Meir J. Stampfer. (2003) Does Vitamin E Supplementation Prevent Cardiovascular Events?. Journal of Women's Health 12:2, 123-136
     CrossRef

267. 267

     Ishwarlal Jialal, Sridevi Devaraj. 2003. Prospective Vitamin E Clinical Trials. .
     CrossRef

268. 268

     Ute Obermuller-Jevic a, Lester Packer b. 2003. Vitamin E. .
     CrossRef

269. 269

     Carol Johnston. 2003. Potential Adverse Effects of Vitamins C and E. .
     CrossRef

270. 270

     Ute Obermuller-Jevic b, Lester Packer a. 2003. Vitamin E in Disease Prevention and Therapy. .
     CrossRef

271. 271

     Joanne Terentis a, Roland "Stocker a,b", Leonard "Kritharides b,c", Andrew Upston a. 2003. Is There a Role for Vitamin E in the Prevention of Atherosclerosis?. .
     CrossRef

272. 272

     Edzard Schwedhelm, Renke Maas, Raphael Troost, Rainer H B??ger. (2003) Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress. Clinical Pharmacokinetics 42:5, 437-459
     CrossRef

273. 273

     Michael H. Davidson, Chris T. Geohas. (2003) Efficacy of over-the-counter nutritional supplements. Current Atherosclerosis Reports 5:1, 15-21
     CrossRef

274. 274

     George A. Stouffer, Richard G. Sheahan, Steven J. Riley, George A. Stouffer. (2003) The Antioxidant Vitamins and Coronary Heart Disease: Part II. Randomized Clinical Trials. The American Journal of the Medical Sciences 325:1, 15-19
     CrossRef

275. 275

     Lesley J. Johnson, Susan L. Meacham, Laura J. Kruskall. (2003) The Antioxidants-Vitamin C, Vitamin E, Selenium, and Carotenoids. Journal of Agromedicine 9:1, 65-82
     CrossRef

276. 276

     William W Parmley. (2003) In the statin era, how important are intense lifestyle changes?. Journal of the American College of Cardiology 41:2, 273-274
     CrossRef

277. 277

     Ulrich Hink, Nikos Tsilimingas, Maria Wendt, Thomas M??nzel. (2003) Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus. Treatments in Endocrinology 2:5, 293-304
     CrossRef

278. 278

     C. P. M. Leeson, A. Mann, M. Kattenhorn, J. E. Deanfield, A. Lucas, D. P. R. Muller. (2002) Plasma vitamin E, total antioxidant status and vascular function in young adults. European Journal of Clinical Investigation 32:12, 889-894
     CrossRef

279. 279

     Noriaki Kume, Toru Kita. (2002) Roles of oxidized low-density lipoprotein and its receptors in the pathogenesis of atherosclerotic diseases. Geriatrics and Gerontology International 2:4, 172-178
     CrossRef

280. 280

     Jim Mann. (2002) Discrepancies in nutritional recommendations: the need for evidence based nutrition. Asia Pacific Journal of Clinical Nutrition 11:s3, S510-S515
     CrossRef

281. 281

     Antonio Silvestro, Francesco Scopacasa, Gabriella Oliva, Tiziana de Cristofaro, Luigi Iuliano, Gregorio Brevetti. (2002) Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis 165:2, 277-283
     CrossRef

282. 282

     Qing Su, Kevin G Rowley, Nicholas D.H Balazs. (2002) Carotenoids: separation methods applicable to biological samples. Journal of Chromatography B 781:1-2, 393-418
     CrossRef

283. 283

     R SAMSON. (2002) Miscellaneous medications for the management of atherosclerosis: Mayhem or miracle?. Seminars in Vascular Surgery 15:4, 275-287
     CrossRef

284. 284

     Brett L. Cucchiara, Scott E. Kasner. (2002) Atherosclerotic risk factors in patients with ischemic cerebrovascular disease. Current Treatment Options in Neurology 4:6, 445-453
     CrossRef

285. 285

     Bibi Hasanain, Arshag D. Mooradian. (2002) Antioxidant vitamins and their influence in diabetes mellitus. Current Diabetes Reports 2:5, 448-456
     CrossRef

286. 286

     Ezra A. Amsterdam. (2002) Lower Is Better: The Heart Protection Study. Preventive Cardiology 5:4, 166-167
     CrossRef

287. 287

     A. Fisher, J. E. Morley. (2002) Editorial: Antiaging Medicine: The Good, the Bad, and the Ugly. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:10, M636-M639
     CrossRef

288. 288

     Andrea Harris, Sridevi Devaraj, Ishwarlal Jialal. (2002) Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Current Atherosclerosis Reports 4:5, 373-380
     CrossRef

289. 289

     JI Mann. (2002) Diet and risk of coronary heart disease and type 2 diabetes. The Lancet 360:9335, 783-789
     CrossRef

290. 290

     Hertzel C. Gerstein. (2002) Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes/Metabolism Research and Reviews 18:S3, S82-S85
     CrossRef

291. 291

     Tom G.P. Saldeen, Jawahar L. Mehta. (2002) Dietary modulations in the prevention of coronary artery disease: a special emphasis on vitamins and fish oil. Current Opinion in Cardiology 17:5, 559-567
     CrossRef

292. 292

     Francesco Cosentino, Massimo Volpe. (2002) Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. Journal of Hypertension 20:9, 1721-1724
     CrossRef

293. 293

     R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, W. E. Wright. (2002) Is There an Antiaging Medicine?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:9, B333-B338
     CrossRef

294. 294

     Eva Lonn, Rosa Roccaforte, Qilong Yi, Gilles Dagenais, Peter Sleight, Jackie Bosch, Pamela Suhan, Mary Micks, Jeffrey Probstfield, Victoria Bernstein, Salim Yusuf. (2002) Effect of long-term therapy with ramipril in high-risk women. Journal of the American College of Cardiology 40:4, 693-702
     CrossRef

295. 295

     Mike Mackness, Jacques Rossouw. (2002) The Heart Protection Study: death knell for the oxidation theory of atherosclerosis?. Current Opinion in Lipidology 13:4, 355
     CrossRef

296. 296

     Theodore Kotchen, Jane Morley Kotchen. 2002. Nutrition and Cardiovascular Health. , 23-43.
     CrossRef

297. 297

     (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 360:9326, 23-33
     CrossRef

298. 298

     Abdelouahed Khalil. (2002) Mécanisme moléculaire de l'effet protecteur de la vitamine E dans l'athérosclérose. Canadian Journal of Physiology and Pharmacology 80:7, 662-669
     CrossRef

299. 299

     John F. Keaney, Joseph A. Vita. (2002) Vascular Oxidative Stress and Antioxidant Protection in Atherosclerosis. Journal of Cardiopulmonary Rehabilitation 22:4, 225-233
     CrossRef

300. 300

     Salim Yusuf. (2002) Two decades of progress in preventing vascular disease. The Lancet 360:9326, 2-3
     CrossRef

301. 301

     Lindsay Brown, Sheila A Doggrell. (2002) Present and future pharmacotherapy for heart failure. Expert Opinion on Pharmacotherapy 3:7, 915-930
     CrossRef

302. 302

     Peter Sleight, Janice Pogue, Salim Yusuf. (2002) Blood pressure and cardiovascular risk in the HOPE study. The Lancet 359:9323, 2118
     CrossRef

303. 303

     JH John, S Ziebland, P Yudkin, LS Roe, HAW Neil. (2002) Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. The Lancet 359:9322, 1969-1974
     CrossRef

304. 304

     Giovambattista Desideri, Giuseppe Croce, Maria Contina Marinucci, Pier Giorgio Masci, Massimo Stati, Letizia Valeri, Anna Santucci, Claudio Ferri. (2002) Prolonged, low dose α-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation. Clinica Chimica Acta 320:1-2, 5-9
     CrossRef

305. 305

     Meilin Liu, Rolf Wallin, Agneta Wallmon, Tom Saldeen. (2002) Mixed Tocopherols Have a Stronger Inhibitory Effect on Lipid Peroxidation Than α-Tocopherol Alone. Journal of Cardiovascular Pharmacology 39:5, 714-721
     CrossRef

306. 306

     Mohsen Meydani. (2002) The Boyd Orr Lecture: Nutrition interventions in aging and age-associated disease. Proceedings of the Nutrition Society 61:02, 165-171
     CrossRef

307. 307

     Norman J Temple. (2002) Nutrition and disease: challenges of research design. Nutrition 18:4, 343-347
     CrossRef

308. 308

     Mark A Moyad. (2002) Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 59:4, 20-33
     CrossRef

309. 309

     R. Ricciarelli, J.-M. Zingg, A. Azzi. (2002) The 80th Anniversary of Vitamin E: Beyond Its Antioxidant Properties. Biological Chemistry 383:3-4, 457-465
     CrossRef

310. 310

     Mark A Moyad. (2002) Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?. Urology 59:4, 9-19
     CrossRef

311. 311

     Jeffrey B. Blumberg. (2002) An Update: Vitamin E Supplementation and Heart Disease. Nutrition in Clinical Care 5:2, 50-55
     CrossRef

312. 312

     Andreas Papas. 2002. Beyond _-Tocopherol. .
     CrossRef

313. 313

     Albert Ferro. (2002) Statins and vascular protection: a ‘radical’ view. Journal of Hypertension 20:3, 359-361
     CrossRef

314. 314

     Peter Steer, Jonas Millgård, Dennis M. Sarabi, Samar Basu, Bengt Vessby, Thomas Kahan, Magnus Edner, Lars Lind. (2002) Cardiac and vascular structure and function are related to lipid peroxidation and metabolism. Lipids 37:3, 231-236
     CrossRef

315. 315

     Ahmed El-Sohemy, Ana Baylin, Donna Spiegelman, Alberto Ascherio, Hannia Campos. (2002) Dietary and Adipose Tissue Gamma-Tocopherol and Risk of Myocardial Infarction. Epidemiology 13:2, 216-223
     CrossRef

316. 316

     James C Fang, Scott Kinlay, John Beltrame, Hiroyuki Hikiti, Marco Wainstein, Dominik Behrendt, Jung Suh, Balz Frei, Gilbert H Mudge, Andrew P Selwyn, Peter Ganz. (2002) Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. The Lancet 359:9312, 1108-1113
     CrossRef

317. 317

     Mark A Moyad. (2002) The placebo effect and randomized trials: analysis of alternative medicine. Urologic Clinics of North America 29:1, 135-155
     CrossRef

318. 318

     Jessica C. Song, C. Michael White. (2002) Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors. Clinical Pharmacokinetics 41:3, 207-224
     CrossRef

319. 319

     Denise D. Hermann. (2002) Naturoceutical Agents in the Management of Cardiovascular Disease. American Journal of Cardiovascular Drugs 2:3, 173-196
     CrossRef

320. 320

     Cynthia M. Carlsson, Kristi Papcke-Benson, Molly Carnes, Patrick E. McBride, James H. Stein. (2002) Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. Drugs & Aging 19:10, 793-805
     CrossRef

321. 321

     Jean-Claude Tardif, Jean Gr??goire, Philippe L. L??Allier. (2002) Prevention of Restenosis with Antioxidants. American Journal of Cardiovascular Drugs 2:5, 323-334
     CrossRef

322. 322

     Chris M. Florkowski. (2002) Management of Co-Existing Diabetes Mellitus and Dyslipidemia. American Journal of Cardiovascular Drugs 2:1, 15-21
     CrossRef

323. 323

     Willett, Walter C., Stampfer, Meir J., . (2001) What Vitamins Should I Be Taking, Doctor?. New England Journal of Medicine 345:25, 1819-1824
     Full Text

324. 324

     Eva Lonn. (2001) Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking. Journal of the American College of Cardiology 38:7, 1795-1798
     CrossRef

325. 325

     Aileen Robertson. (2001) Social inequalities and the burden of food-related ill-health. Public Health Nutrition 4:6a,
     CrossRef

326. 326

     Brendan M McQuillan, Joseph Hung, John P Beilby, Mark Nidorf, Peter L Thompson. (2001) Antioxidant vitamins and the risk of carotid atherosclerosis. Journal of the American College of Cardiology 38:7, 1788-1794
     CrossRef

327. 327

     James W. Schnell, Rachel A. Anderson, Jane E. Stegner, Stephen P. Schindler, Richard B. Weinberg. (2001) Effects of a high polyunsaturated fat diet and vitamin E supplementation on high-density lipoprotein oxidation in humans. Atherosclerosis 159:2, 459-466
     CrossRef

328. 328

     Freedman, Jane E., . (2001) Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions. New England Journal of Medicine 345:22, 1636-1637
     Full Text

329. 329

     Brown, B. Greg, Zhao, Xue-Qiao, Chait, Alan, Fisher, Lloyd D., Cheung, Marian C., Morse, Josh S., Dowdy, Alice A., Marino, Emily K., Bolson, Edward L., Alaupovic, Petar, Frohlich, Jiri, Serafini, Leny, Huss-Frechette, Ellen, Wang, Shari, DeAngelis, Debbie, Dodek, Arthur, Albers, John J., . (2001) Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. New England Journal of Medicine 345:22, 1583-1592
     Full Text

330. 330

     Owen L Woodman. (2001) Pharmacological approaches to preserving and restoring coronary endothelial function. Expert Opinion on Pharmacotherapy 2:11, 1765-1775
     CrossRef

331. 331

     Diane L. Tribble. (2001) Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. Coronary Artery Disease 12:7, 541-546
     CrossRef

332. 332

     Lynn Greig, Simon Maxwell. (2001) Anti-oxidants - a protective role in cardiovascular disease?. Expert Opinion on Pharmacotherapy 2:11, 1737-1750
     CrossRef

333. 333

     Alicia J Jenkins, James D Best. (2001) Novel agents for managing dyslipidaemia. Expert Opinion on Investigational Drugs 10:11, 1901-1911
     CrossRef

334. 334

     Junya Shite, Fuzhong Qin, Weike Mao, Hiroya Kawai, Suzanne Y Stevens, Chang-seng Liang. (2001) Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. Journal of the American College of Cardiology 38:6, 1734-1740
     CrossRef

335. 335

     Christopher D. Gardner. (2001) The role of plant-based diets in the treatment and prevention of coronary artery disease. Coronary Artery Disease 12:7, 553-559
     CrossRef

336. 336

     Claudio Napoli, Filomena de Nigris, Wulf Palinski. (2001) Multiple role of reactive oxygen species in the arterial wall. Journal of Cellular Biochemistry 82:4, 674-682
     CrossRef

337. 337

     Domenic A. Sica. (2001) The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. Current Opinion in Nephrology and Hypertension 10:5, 597-601
     CrossRef

338. 338

     Renee P. Lauber, Nancy F. Sheard. (2001) The American Heart Association Dietary Guidelines for 2000: A Summary Report. Nutrition Reviews 59:9, 298-306
     CrossRef

339. 339

     Volker Schächinger, Andreas M. Zeiher. (2001) Prognostic implications of endothelial dysfunction: does it mean anything?. Coronary Artery Disease 12:6, 435-443
     CrossRef

340. 340

     Domenic A. Sica. (2001) Prematurely Terminated Clinical Trials and Their Application to Cardiovascular Medicine. Congestive Heart Failure 7:5, 265-271
     CrossRef

341. 341

     P. Gaede, H. E. Poulsen, H.-H. Parving, O. Pedersen. (2001) Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabetic Medicine 18:9, 756-760
     CrossRef

342. 342

     Julian P.J. Halcox, Arshed A. Quyyumi. (2001) Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. Coronary Artery Disease 12:6, 475-484
     CrossRef

343. 343

     Lawrence K. Chang, Duane C. Whitaker. (2001) The Impact of Herbal Medicines on Dermatologic Surgery. Dermatologic Surgery 27:8, 759-763
     CrossRef

344. 344

     Jiri Neuzil, Christian Weber, Anatol Kontush. (2001) The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherosclerosis 157:2, 257-283
     CrossRef

345. 345

     Antonio M. Gotto, John A. Farmer. (2001) Pleiotropic effects of statins: do they matter?. Current Opinion in Lipidology 12:4, 391-394
     CrossRef

346. 346

     Simin Liu, JoAnn E. Manson. (2001) Dietary carbohydrates, physical inactivity, obesity, and the ‘metabolic syndrome’ as predictors of coronary heart disease. Current Opinion in Lipidology 12:4, 395-404
     CrossRef

347. 347

     Ryuichi Mashima, Paul K. Witting, Roland Stocker. (2001) Oxidants and antioxidants in atherosclerosis. Current Opinion in Lipidology 12:4, 411-418
     CrossRef

348. 348

     Domenic Sica. (2001) Lessons learned from prematurely terminated clinical trials. Current Hypertension Reports 3:4, 360-366
     CrossRef

349. 349

     Tom J. Jeerakathil, Philip A. Wolf. (2001) Prevention of strokes. Current Atherosclerosis Reports 3:4, 321-327
     CrossRef

350. 350

     M Törnwall. (2001) α-Tocopherol (vitamin E) and β-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial. Atherosclerosis 157:1, 167-173
     CrossRef

351. 351

     Rafael J. Gaytan, L. Michael Prisant. (2001) Oral Nutritional Supplements and Heart Disease: A Review. American Journal of Therapeutics 8:4, 255-274
     CrossRef

352. 352

     Shawn D. Hingtgen, Robin L. Davisson. (2001) Gene Therapeutic Approaches to Oxidative Stress-Induced Cardiac Disease: Principles, Progress, and Prospects. Antioxidants & Redox Signaling 3:3, 433-449
     CrossRef

353. 353

     Klaus K.A. Witte, Andrew L. Clark, John G.F. Cleland. (2001) Chronic heart failure and micronutrients. Journal of the American College of Cardiology 37:7, 1765-1774
     CrossRef

354. 354

     (2001) Mega-trial of vitamin E yields negative result. Focus on Alternative and Complementary Therapies 6:2, 129-130
     CrossRef

355. 355

     Claudio Napoli, Lilach O. Lerman. (2001) Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. Mayo Clinic Proceedings 76:6, 619-631
     CrossRef

356. 356

     C Napoli, L O Lerman. (2001) Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia.. Mayo Clinic Proceedings 76:6, 619-631
     CrossRef

357. 357

     Lee Hooper, Andrew R Ness, George Davey Smith. (2001) Antioxidant strategy for cardiovascular disease. The Lancet 357:9269, 1705
     CrossRef

358. 358

     Maria Carla Roncaglioni, Massimo Tombesi, Chiara Chiabrando, Vittorio Bertele. (2001) Antioxidant strategy for cardiovascular disease. The Lancet 357:9269, 1706
     CrossRef

359. 359

     Craig H Selzman. (2001) Current approaches to therapy for vascular injury. Expert Opinion on Pharmacotherapy 2:5, 753-764
     CrossRef

360. 360

     Asim K. Dutta-Roy. (2001) Therapy and clinical trials. Current Opinion in Lipidology 12:2, 239-241
     CrossRef

361. 361

     Peter M Abuja, Riccardo Albertini. (2001) Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clinica Chimica Acta 306:1-2, 1-17
     CrossRef

362. 362

     Brent M. Egan, Eddie L. Greene, Theodore L. Goodfriend. (2001) Nonesterified fatty acids in blood pressure control and cardiovascular complications. Current Hypertension Reports 3:2, 107-116
     CrossRef

363. 363

     John A. Farmer, Guillermo Torre-Amione. (2001) The renin angiotensin system as a risk factor for coronary artery disease. Current Atherosclerosis Reports 3:2, 117-124
     CrossRef

364. 364

     Sarah L Nuttall, Martin J Kendall, Jonathan N Townend, David C Wheeler. (2001) Vitamin E supplementation. The Lancet 357:9256, 631
     CrossRef

365. 365

     Rory Collins, Stephen MacMahon. (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. The Lancet 357:9253, 373-380
     CrossRef

366. 366

     Ishwarlal Jialal, Maret Traber, Sridevi Devaraj. (2001) Is there a vitamin E paradox?. Current Opinion in Lipidology 12:1, 49-53
     CrossRef

367. 367

     Alice H. Lichtenstein. (2001) Approaches to reducing cardiovascular disease risk: food or pills?. Current Opinion in Lipidology 12:1, 1-3
     CrossRef

368. 368

     Anastasios Gazis, Andrew Fogarty. (2001) Vitamin E supplementation. The Lancet 357:9256, 631-632
     CrossRef

369. 369

     Matthew R. Weir, Roland C. Blantz. (2001) Implications from the Heart Outcomes Prevention Evaluation Study. Current Opinion in Nephrology and Hypertension 10:1, 61-63
     CrossRef

370. 370

     Etsuo NIKI. (2001) Lipid Peroxidation and Its Inhibition: Overview and Perspectives.. Journal of Oleo Science 50:5, 313-320
     CrossRef

371. 371

     Walter W Rosser. (2001) Aspirin for primary prevention of cardiovascular events. The Lancet 357:9250, 84-85
     CrossRef

372. 372

     Roberto Marchioli, Carlo Schweiger, Giacomo Levantesi, Luigi Tavazzi, Franco Valagussa. (2001) Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data. Lipids 36:S1, S53-S63
     CrossRef

373. 373

     Werner O. Richter. (2001) Applications of fatty acid derivatives and antioxidants in dietary lipids. European Journal of Lipid Science and Technology 103:1, 42-45
     CrossRef

374. 374

     Supriya Kaushik, Rosemary Wander, Scott Leonard, Bruce German, Maret G. Traber. (2001) Removal of fat from Cow's milk decreases the vitamin E contents of the resulting dairy products. Lipids 36:1, 73-78
     CrossRef

375. 375

     Maria Carla Roncaglioni. (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. The Lancet 357:9250, 89-95
     CrossRef

376. 376

     Hans Fritz, Marianne Jochum, Werner Müller-Esterl. (2001) Kinins 1925-2000. Biological Chemistry 382:1, 3-4
     CrossRef

377. 377

     G. R. de Freitas, J. Bogousslavsky. (2001) Primary stroke prevention. European Journal of Neurology 8:1, 1-15
     CrossRef

378. 378

     Matthew R. Weir. (2000) Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?. Current Hypertension Reports 2:6, 497-499
     CrossRef

379. 379

     Daniel Steinberg. (2000) Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?. Current Opinion in Lipidology 11:6, 603-607
     CrossRef

380. 380

     T S Tsang, M E Barnes, B J Gersh, S N Hayes. (2000) Risks of coronary heart disease in women: current understanding and evolving concepts.. Mayo Clinic Proceedings 75:12, 1289-1303
     CrossRef

381. 381

     Daniel Bunout. (2000) Therapeutic potential of vitamin E in heart disease. Expert Opinion on Investigational Drugs 9:11, 2629-2636
     CrossRef

382. 382

     David J.A Jenkins, Cyril W.C Kendall, Edward Vidgen, Vladimir Vuksan, Chung-Ja Jackson, Livia S.A Augustin, Brenda Lee, Marcella Garsetti, Sanjiv Agarwal, A.Venket Rao, Gloria B Cagampang, Victor Fulgoni. (2000) Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein. Metabolism 49:11, 1496-1500
     CrossRef

383. 383

     Hannele Yki-J??rvinen. (2000) Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Drugs 60:5, 975-983
     CrossRef

384. 384

     Nancy F. Sheard, Nathaniel G. Clark. (2000) The Role of Nutrition Therapy in the Management of Diabetes Mellitus. Nutrition in Clinical Care 3:6, 334-348
     CrossRef

385. 385

     Marc A. Forgione, Jane A. Leopold, Joseph Loscalzo. (2000) Roles of endothelial dysfunction in coronary artery disease. Current Opinion in Cardiology 15:6, 409-415
     CrossRef

386. 386

     Ruth M. DeBusk. (2000) Dietary supplements and cardiovascular disease. Current Atherosclerosis Reports 2:6, 508-514
     CrossRef

387. 387

     Angel Montero, Karen A. Munger, Rizwan Z. Khan, Jose M. Valdivielso, Jason D. Morrow, Antonio Guasch, Fuad N. Ziyadeh, Kamal F. Badr. (2000) F2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney International 58:5, 1963-1972
     CrossRef

388. 388

     Simon Maxwell, William S. Waring. (2000) Therapeutics Drugs used in secondary prevention after myocardial infarction: Case presentation. British Journal of Clinical Pharmacology 50:5, 405-417
     CrossRef

389. 389

     Margaret E. Brousseau, Ernst J. Schaefer. (2000) Diet and coronary heart disease: Clinical trials. Current Atherosclerosis Reports 2:6, 487-493
     CrossRef

390. 390

     Tom A.B. Sanders. (2000) Nutrition and metabolism. Current Opinion in Lipidology 11:5, 551-553
     CrossRef

391. 391

     M Boaz, S Smetana, T Weinstein, Z Matas, U Gafter, A Iaina, A Knecht, Y Weissgarten, D Brunner, M Fainaru, MS Green. (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. The Lancet 356:9237, 1213-1218
     CrossRef

392. 392

     Dayuan Li, Tom Saldeen, Jawahar L. Mehta. (2000) Effects of ??-Tocopherol on ox-LDL-Mediated Degradation of I??B and Apoptosis in Cultured Human Coronary Artery Endothelial Cells. Journal of Cardiovascular Pharmacology 36:3, 297-301
     CrossRef

393. 393

     Donald S McLaren. (2000) A trawl through the current nutrition literature. Nutrition 16:9, 782-784
     CrossRef

394. 394

     Lawrence M Title, Peter M Cummings, Karen Giddens, Jacques J Genest, Bassam A Nassar. (2000) Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. Journal of the American College of Cardiology 36:3, 758-765
     CrossRef

395. 395

     James S. Forrester. (2000) Prevention. Current Opinion in Cardiology 15:5, 343-347
     CrossRef

396. 396

     Sridevi Devaraj, Ishwarlal Jialal. (2000) Antioxidants and vitamins to reduce cardiovascular disease. Current Atherosclerosis Reports 2:4, 342-351
     CrossRef

397. 397

     Gilles R. Dagenais, Roberto Marchioli, Gianni Tognoni, Salim Yusuf. (2000) Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Current Cardiology Reports 2:4, 293-299
     CrossRef

398. 398

     (2000) Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. New England Journal of Medicine 342:25, 1917-1918
     Full Text

399. 399

     Pocock, Stuart J., Elbourne, Diana R., . (2000) Randomized Trials or Observational Tribulations?. New England Journal of Medicine 342:25, 1907-1909
     Full Text

400. 400

     Naranjan S. Dhalla, Rana M. Temsah, Thomas Netticadan. (2000) Role of oxidative stress in cardiovascular diseases. Journal of Hypertension 18:6, 655-673
     CrossRef

401. 401

     Rudolph A. Riemersma. (2000) Sense or nonsense?. European Journal of Lipid Science and Technology 102:5, 322-322
     CrossRef

402. 402

     John A. Farmer. (2000) Coronary heart disease: Clinical trials review. Current Atherosclerosis Reports 2:3, 189-193
     CrossRef

403. 403

     Anne P. Spencer. (2000) Vitamin E: Cautionary issues. Current Treatment Options in Cardiovascular Medicine 2:3, 193-195
     CrossRef

404. 404

     Anne P. Spencer. (2000) Vitamin E: cautionary issues. Current Treatment Options in Cardiovascular Medicine 2:2, 1-3
     CrossRef

405. 405

     The Heart Outcomes Prevention Evaluation Study Investigators. (2000) Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine 342:3, 145-153
     Full Text

406. 406

     &NA;. (2000) News in brief .... Inpharma Weekly &NA;:1222, 18
     CrossRef

Letters